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Musculoskeletal injuries inflicted by wars, congenital deformities, tumor resection, and general 
traumatic injuries often require soft tissue reconstruction. Damages to soft tissue not only affect 
cosmetic appearance, but also hinder function and emotional well-being. Autologous adipose 
grafting using processed lipoaspirate is a safe, resourceful, and minimally invasive option gaining 
tremendous momentum in clinical practice due to potential applications in trauma and 
reconstructive surgery, especially for breast cancer reconstruction. However, results can be 
unpredictable due to graft resorption rates reaching as high as 90%. These limitations serve as 
motivation for the development of new therapies to regenerate adipose tissue. We examined the 
use of an injectable adipose derived extracellular matrix (AdECM) combined with dexamethasone 
encapsulated polymer microspheres (Dex MS) as a scaffold for soft tissue restoration. First, we 
implemented a decellularization process to remove lipids and cellular content from discarded 
adipose tissue. The remaining material, known as AdECM, was thoroughly characterized. 
Triglycerides and residual DNA content were significantly reduced to ensure biomaterial safety. 
Adipose matrix proteins and glycosaminoglycans were evident and measurable following the 
decellularization process. Additionally, polymer microsphere encapsulation techniques were used 
to release dexamethasone in a controlled fashion.  
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Christopher Mahoney, Ph.D. 
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Hydrogels derived from AdECM have shown potential in the ability to generate new adipose tissue 
in vivo. To further enhance adipogenesis, a composite adipose derived delivery system (CADDS) 
containing single- and double-walled dexamethasone encapsulated microspheres (SW and DW 
Dex MS) was developed. Previously, our laboratory has published the use of Dex MS as an 
additive to enhance adipogenesis and angiogenesis in adipose tissue grafts. In the current work, 
AdECM and CADDS are extensively characterized, in addition to conducting in vitro cell culture 
analysis. Characterization studies indicate the AdECM used for the CADDS has minimal cellular 
and lipid content allowing for gelation of its collagen structure under physiological conditions. 
Human adipose-derived stem cell (hASC) culture studies confirmed viability with the CADDS, 
and adipogenesis was increased in experimental groups containing the hydrogel scaffold. In vitro 
studies of AdECM hydrogel containing microspheres demonstrated a controlled release of 
dexamethasone from SW and DW formulations. In vivo studies indicated increased volume 
retention from CADDS material implants with Dex MS. Additionally, in vitro studies comparing 
hASCs to rat ASCs (rASCs) showed that hASCs differentiate and accumulate lipids on CADDS 
material at a higher capacity than rASCs. The comparison offers an explanation to the low retention 
rates seen from the animal studies. The delivery of Dex MS via an injectable hydrogel scaffold 
combines two biologically responsive components to develop a minimally invasive, off-the-shelf 
biomaterial for adipose tissue engineering.  
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1.0  INTRODUCTION 
Adipose tissue plays an essential regulatory role in normal substrate metabolism by storing and 
releasing high-energy compounds when the needed by the body. Adipose tissue is found 
throughout the body to protect underlying structures, provide insulation, and impart a typical 
human appearance (Choi et al. 2010; Philips et al. 2012a). Human appearance can become 
compromised by disease, trauma, tumor resection, or congenital defects. Soft adipose tissue 
engineering has recently generated great interest to surgeons treating patients with disfiguring 
contour imperfections, particularly when using autologous fat grafting as a treatment (Philips et 
al. 2012a). Autologous fat grafting, using a patient’s own processed lipoaspirate, has surged in 
recent years as a minimally-invasive solution. Although long-term outcomes of fat graft survival 
and durability still remain highly unpredictable due to post-graft resorption with the possibility of 
as little as ten percent of the original fat volume retained (Choi et al. 2010; Minteer et al. 2015; 
Philips et al. 2012a). The main requirements of adipose tissue engineering can be summarized into 
three main categories: host compatibility, bioactivity, and sustainability. Host compatibility is 
imperative so that the implanted construct does not elicit host immunological rejection. Moreover, 
tissue-specific soft tissue reconstruction would optimize host compatibility (Choi et al. 2010). We 
utilized the tissue-specific approach to design a composite adipose derived delivery system from 
decellularized adipose tissue and dexamethasone encapsulated polymer microspheres for adipose 
tissue defect restoration.  
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1.1 THE CLINICAL NEED FOR ADIPOSE TISSUE RECONSTRUCTION 
Adipose tissue is distributed throughout the body and is categorized by location such as 
subcutaneous (arm, abdominal, and gluteal), intraabdominal (omental, retroperitoneal, and 
visceral) and other sites (retroorbital, periarticular regions, bone marrow, intramuscular, and 
pericardial). Adipose tissue performs an essential role in the protection of underlying structures, 
providing insulation, contributing function, and imparting a normal human appearance. This 
appearance, and even function, can be compromised by disease, trauma, tumor resection or 
congenital defects of the subcutaneous adipose tissue. These pathologies and defects of the adipose 
tissue remain a reconstructive challenge for plastic surgeons and clinicians. According to the 
American Society of Plastic Surgeons, the most common reconstructive procedures are breast 
reconstruction, burn care, cleft lip/palate repair, tumor removal, and treatment from dog bites 
(ASPS 2017). In particular, from 2009 to 2014, the Agency for Healthcare Research and Quality 
reported an increase in breast reconstruction after mastectomy by 62 percent (Miller et al. 2017).   
Two major reconstruction options for breast adipose tissue deficits in the clinic include 
implant-based procedures or flap surgery using the patient’s own skin, fat, and/or muscle. 
Currently, flap surgeries are not without morbidity. Patients receiving autologous reconstruction 
are at high risk for specific complications including wound infection, flap/prosthesis failure, and 
reoperation. Additionally, general complications of major surgery such as deep vein thrombosis, 
blood transfusions, pneumonia, and pulmonary embolism can lead to a prolonged length of stay in 
the hospital (Agha, Goodacre, and Orgill 2013b; Tachi and Yamada 2005).  Implant-based breast 
reconstruction is the most frequently used technique globally (Schmauss et al. 2016). The first 
documented implant-based breast reconstruction was performed by Vincent Czerny in 1895 using 
the patient’s lipoma to augment a post-surgical asymmetry after tumor resection (Champaneria et 
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al. 2012). Implant-based procedures require adequate skin envelope that allows covering the 
implant that is normally introduced in a sub-muscular plane detaching the medial insertions of the 
pectoralis major muscle from the ribs. The most common implants are silicone gel-filled breast 
implants that contain a highly viscous and more or less form-stable gel. Implants are available in 
a variety of shapes and sizes (Schmauss et al. 2016). Patients undergoing implant-based 
reconstruction may encounter complications such as rupture, migration, discontent, implant 
exposure/extrusion, rippling, and deformation/distortion (Rocco et al. 2016). These complications 
can occur during the subsequent 10 years following the procedure with a risk of reoperation of 
70% (Schmauss et al. 2016). With the volume of complications to consider using invasive 
procedures such as flap and implant-based surgeries, clinicians and patients are looking for less or 
minimally invasive options.   
In effort to reduce the risk of complications, clinicians have increased the practice of a 
widely-used procedure in plastic surgery known as autologous fat grafting (AFG). Assuming the 
patient has adipose tissue to spare, which is not always the case, AFG harvests the patient’s own 
fat, typically from the abdomen or thighs, via liposuction and deposits the tissue into the defect 
site with syringe injections. AFG is minimally invasive and carries several advantages in 
comparison to implant- or flap-based soft tissue reconstruction. With minimal scarring from the 
defect site and no foreign body reaction, the patient recovery time is typically less than 48 hours.  
Depending on the clinical indication, the standard of care for adipose tissue repair and 
regeneration may vary as well as their outcomes. For cases such as breast reconstruction, 
lipoatrophy, scleroderma, face rejuvenation, gluteal augmentation, cranio-maxilla-facial 
deformities, etc., the gold standard of care is an AFG (Monfort and Izeta 2012). AFG is a safe, 
resourceful, and minimally invasive option which allows the patient’s body to provide its own 
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non-immunogenic, compatible biomaterial (Agha, Goodacre, and Orgill 2013a, Hong et al. 2010a, 
Gir et al. 2012a). The liposuction technique and fat processing of AFG has significantly evolved 
over the past century with the advancement of technologies used to perform the procedure and 
examination of studies to optimize graft survival. As shown in Figure 1, many plastic and 
reconstructive surgeons have adopted the “lipo-structure technique” or Coleman technique for the 
microinjection of fat particles to minimize fat graft loss (Mahoney et al. 2018). Using a Coleman 
microcannula, light negative pressure is created by drawing the plunger of a 10-ml syringe 
connected to a 3-mm cannula when introduced in the subcutaneous cavity per a small incision. 
The cannula is moved through the adipose section manually, loosening the tissue, and collecting 
the fat into the syringe. For processing, the collected fat tissue is transferred to 10 mL tubes for 
centrifugation to separate into four layers: (a) oily fraction; (b) aqueous fraction; (c) a cell pellet; 
and (d) the purified fat flanked by the oily and aqueous fractions (Simonacci et al.). Centrifugation 
at 3000 rpm for 3 min is the standard for separation of fractions, but there is literature that suggests 
slower speeds may reduce adipocyte disruption (Gir et al. 2012a). Following centrifugation, the 
middle layer of viable adipocytes is transferred to 1 cc syringes. Successful graft implantation is 
executed using blunt tip cannulas to create tunnels at insertion, with small aliquots of fat injected 
at different depths of the defect. Multiple passes are utilized to reach throughout the site of interest. 
Due to the unpredictable volume results from AFG, the majority of clinicians overcorrect volume 
deficiencies from 20-30% (Kaufman et al. 2007, Tabit et al. 2012).  
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Figure 1. Lipo-structure technique for autologous fat grafting (Mahoney et al. 2018) 
Adipose grafts contain adipose derived stem cells (ASCs) with the capability of 
differentiating into various cell lineages in the correct environment (Maione et al. 2015). Other 
advantages of ASCs include the expression/secretion of growth factors such as IGF (insulin-like 
growth factor), HGF (hepatocyte growth factor), TGF-1 (transforming growth factor beta 1) and 
VEGF (vascular endothelial growth factor). Several studies have shown that the addition of ASCs 
to increase stem cell content of the fat graft lead to healthier engraftment (Philips, Marra, and 
Rubin 2012, Choi et al. 2014a). Protocols involving the injection of ASCs from the stromal 
vascular fraction (SVF), seen in Figure 2, of processed adipose tissue require an additional 
operation. However, while the general outcomes for these procedures are successful in the short-
term, the long-term results can be unpredictable due to post-graft resorption rates reaching as high 
as 90% (Monfort and Izeta 2012, Hong et al. 2010a). These studies demonstrated no evidence to 
support an improved protocol (Gir et al. 2012b, Yu et al. 2015). Although fat transplantation 
techniques have been refined and enhanced in recent years, further improvement is required due 
to the continued lack of predictability in volume restoration. Several techniques have been 
evaluated for their differences in fat harvesting, fat processing, fat reinjection, and fat storage. 
 6 
 
 
Figure 2. Cellular and Extracellular Constituents of Adipose Tissue and SVF 
While AFG is a widely utilized treatment, there can be complications. Experienced 
physicians using the preferred technique may encounter unsatisfactory results such as fat necrosis, 
calcification, oil cyst formation, and hypertrophic scarring (Simonacci et al. , Gir et al. 2012a, 
Nahabedian 2015, Philips, Marra, and Rubin 2014). Largo et al. reviewed several publications 
following the results of over 1400 patients (Largo et al. 2014). The studies containing volume 
retention data documented values varying from 55 to 82 percent retention. Other studies have 
reported resorption rates from 30 to 70 percent (Kaufman et al. 2007, Kurita et al. 2008). There 
are several mechanisms that contribute to the variability of outcomes from AFG. The trauma 
caused by liposuction can lead to apoptosis of adipocytes and cyst formation. The different degrees 
of blood supply and fluctuations in oxygen delivery of the recipient wound may range from 
adequate revascularization to insufficient revascularization and ischemia, apoptosis, and 
dedifferentiation of essential adipocytes.  An accepted principle of fat grafting is that adipocytes 
within 2 mm of an arterial blood supply have greatest chance of survival (Tabit et al. 2012, Bourne 
et al. 2016). Overall, autologous fat grafting is limited by graft absorption and necrosis due to lack 
of vascularization after fat transfer. 
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1.2 ADIPOSE TISSUE ENGINEERING 
Tissue engineers have begun to address the challenges of variable resorption of autologous fat 
grafting with strategies to engineer tissue tailored to a specific site of injury (Keck et al. 2011a, 
Jennifer H. Choi 2010). Synthetic polymer biomaterials for adipose tissue engineering have the 
advantage of being able to tailor mechanical properties, chemical properties, and degradability. In 
addition, a number of biologically derived materials, such as collagen, hyaluronic acid, fibrin, and 
alginate, have been utilized as injectable scaffolds for soft tissue repair and shown successful 
adipose tissue growth (Hemmrich and von Heimburg 2006). However, significant work in vivo 
remains in order to confirm and optimize treatments for clinical use, including investigating the 
role of macrophage in the remodeling process following implantation. Since the extracellular 
matrix of each tissue and organ consists of specialized secreted products for its resident cell 
population, it would be appropriate to develop an injectable hydrogel from adipose tissue as 
replacement material that contains the constitutive peptides, cytokines, and complement factors 
which regulate cell growth, vascularization and homeostasis (Choi et al. 2014b, Cheung et al. 
2014b, Sano et al. 2014, Choi et al. 2011). 
Adipose tissue engineering requires the essential permutation of bioactivity, sustainability, 
and host compatibility. Several studies have shown that tissue site influences both amount of 
adipose tissue regeneration and metabolic function of regenerated tissue. Schipper et al. 
demonstrated that human adipose-derived stem cells harvested from various subcutaneous depots 
exhibited significant differences in adipogenic differentiation, sensitivity to apoptosis, and 
lipolytic function (Schipper et al. 2008). A review by Giorgino et al. describes the metabolic and 
hormonal differences between fat depots, as well as the different signaling properties of distinct 
fat depots (Giorgino, Laviola, and Eriksson 2005). Hence, there needs to be a thorough 
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understanding in the design of an engineered adipose tissue construct. Similarly, it is necessary to 
thoroughly characterize the biological and mechanical properties of an implanted biomaterial, as 
the construct is typically degraded as new adipose tissue and extracellular matrix is remolded (Sano 
et al. 2014).  
Bioactivity of the regenerated adipose tissue needs to mimic that of native adipose tissue, 
not only in function, but also in structure, which includes the incorporation of a functional 
vasculature consisting of blood vessels, nerves, and lymphatic vessels. Incorporation of the 
construct upon transplantation is also critical, as the ability of the tissue to completely regenerate 
over the long term without associated donor-site morbidity or loss of function with time is essential 
for full restoration of native tissue function. There are several assays that are commonly used to 
evaluate the biochemical functions of adipose tissue resulting from an engineered construct. 
Mature adipocytes, the predominant cell type in the adipose tissue, contain microscopic 
intracellular lipid droplets, which are the first visible signs of adipose tissue formation. Nile red, 
Oil Red O staining and enzymatic assays are conducted to observe and quantify the intracellular 
lipid, respectively (Gerlach et al. 2012, Minteer, Marra, and Rubin 2015). Real-time reverse 
transcription polymer chain reaction (RT-PCR) is also implemented in analysis to detect specific 
transcripts related to adipogenic differentiation and lipogenic activity. Key transcription factors 
that are measured most frequently include peroxisome proliferator-activated receptor-gamma 
(PPAR-γ), glucose transporter-4 (Glut4), fatty acid binding protein-4 (FABP4), and acyl-CoA 
synthetase (ACS) (Sano et al. 2014, Choi et al. 2011, Poon et al. 2013, Young et al. 2011). 
Glycerol-3-phosphate dehydrogenase (GDPH), a key enzyme in triacylglycerol biosynthesis, is 
frequently detected at the levels of both transcript and activity (Rubin et al. 2009b, Giorgino, 
Laviola, and Eriksson 2005). Another key measure of adipose function is its sensitivity to hormone 
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stimulation. Standard assays involve measurements on glucose uptake or glycerol and fatty acid 
release after stimulation with lipolytic (catecholamine) or lipogenic (insulin) hormones.  
As discussed earlier, adipose tissue is recognized as a vital endocrine organ. Therefore, the 
ability to engineered adipose to secrete appropriate adipokines, such as leptin and adiponectin, 
should be and has been thoroughly investigated. The adipose tissue environment, comprising of 
adipogenic stimulants, inflammatory cytokines, thrombosis-associated cytokines, and growth 
factors, is a complex niche that stimulates and maintain native adipose tissue (Peckett, Wright, and 
Riddell 2011, Rubin et al. 2009b, Choi et al. 2014b). There are several known mediators of adipose 
tissue formation that are commonly exploited. These include the phosphodiesterase inhibitor 3-
isobutyl-1-nethyl-xanthine; the glucocorticoid dexamethasone; indomethacin, an inhibitor of 
cyclooxygenase; and insulin, which is active in glucose uptake and triglyceride formation 
(Minteer, Marra, and Rubin 2015). Basic fibroblast growth factor (bFGF) is an essential growth 
factor present in native adipose tissue that has been widely utilized in adipose tissue engineering 
strategies. In addition, the microenvironment consists of constitutive cell populations, specific pH 
and oxygen levels, and appropriate ECM. Collectively, these key components should be 
considered as the design and analysis of engineered biomaterials should reflect closely the native 
tissue environment.  
In the effort to achieve a sustainable adipose environment, the ability of the new tissue to 
incorporate blood vasculature is important. Vasculature has been incorporated either in vitro 
through the addition of vascular cells or in vivo through the recruitment of host cells and is often 
evaluated through histological analysis for specific endothelial markers such as CD31 and von 
Willebrand factor (Chung et al. 2012b, Schipper et al. 2008, Choi et al. 2014b). Complete 
regeneration of functional adipose tissue and incorporation of functional vasculature will only be 
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attained through long-term analyses of both in vivo and in vitro constructs. This includes 
measurement of viability and function of the engineered/regenerated tissue, as well as ensuring 
minimal donor-site morbidity over the years. Additionally, new ECM production is another 
indicator of mature adipogenesis. Specifically, new ECM deposition, composed of collagen type 
IV, laminin, and fibronectin, plays a role in the maintenance and remodeling of adipose tissue 
(Uriel et al. 2008). Studies have also confirmed the secretion of ECM from human adipose stem 
cells (hASCs) which can be used as a biological scaffold for adipose formation. 
1.3 BIOMATERIALS FOR ADIPOSE TISSUE ENGINEERING 
1.3.1 Synthetic Biomaterials 
Synthetic biomaterials have the advantage of being tailored and specifically designed for 
adjustment of mechanical/chemical properties as well as degradation (Place et al. 2009). Synthetic 
materials such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and poly(lactic-co-glycolic 
acid) (PLGA) have been extensively investigated and used for adipose tissue regeneration (Sharma 
et al. 2015, Patrick et al. 2002, Patrick et al. 1999, Place et al. 2009, Dhandayuthapani et al. 2011, 
Elamparithi et al. 2016, Itoi et al. 2010, Patrick 2001). These polymers degrade via hydrolysis and 
their degradability can be controlled by altering the molecular weight, crystallinity, and ratio of 
lactic to glycolic acid subunits (Place et al. 2009).  
As ASCs and SVF are used in AFG retention, these biologics have also been seeded within 
scaffold biomaterials as a therapy for adipose tissue engineering. Patrick et al., demonstrated in 
vivo tissue formation compared ASC-seeded PLGA scaffolds to acellular PLGA scaffolds 
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implanted subcutaneously on the dorsal aspect of Lewis rats for 12 months (Patrick et al. 2002). 
Histological assessment of explanted constructs showed maximum adipose tissue formation at 2 
months for both groups. However, as PLGA scaffolds degraded, adipose tissue volume also 
decreased with time. Long term maintenance of viable adipose tissue was not obtained using the 
preadipocyte-seeded PLGA scaffolds (Patrick et al. 1999, Patrick et al. 2002). Patrick et al., 
continued to analyze synthetic biomaterials to engineer adipose tissue using PLA reinforced PGA 
(Cho et al. 2005). The biodegradable PGA/PLA support scaffold was supplemented with fibrin 
matrix and seeded with human ASCs prior to implantation into subcutaneous pockets of athymic 
mice. After six weeks, adipose tissue formation with scaffold-fibrin matrix containing ASCs 
indicated differentiation in vivo. Implanted scaffolds without ASCs in fibrin gel demonstrated 
limited adipocyte formation (Cho et al. 2005). The survival of adipose tissue beyond six weeks 
was not reported.  It is possible that an immunocompetent animal model with autologous cells may 
provide additional information into the mechanism. These preliminary studies introduced the use 
of ASCs for adipose tissue formation. Several limitations such as time, feasibility, and 
reproducibility have been addressed by investigators. With the maximum adipose tissue formation 
being shown at 2 months, additional therapeutics are needed to provide stronger outcomes in vivo 
with synthetically-based scaffolds. Synthetic materials possess several drawbacks when compared 
to their natural counterparts, particularly the absence of intrinsic surface ligands for cell attachment 
and a potential impact of their degradation products on cell function (Dhandayuthapani et al. 2011, 
Place et al. 2009). These limitations render the use of solely biomaterials for soft tissue repair quite 
challenging. 
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1.3.2 Extracellular Matrix-Derived Materials 
The use of ECM-derived matrices has gained significant interest in tissue engineering due its 
potential to be easily recognized by the host environment. Constitutive ECM proteins retained after 
decellularization are the ideological scaffold material for tissue restoration. An ECM scaffold-
based approach to regeneration will elicit an immediate host response distinctly different from 
other scaffold materials after implantation due to their surface topologies and ligand landscapes 
(Brown, Ratner, et al. 2012). Cellular infiltrate consisting of polymorphonuclear leukocytes and 
mononuclear cells occurs within minutes. After 72 hours, most infiltrating cells are entirely 
mononuclear, specifically of the pro-inflammatory macrophage phenotype (M1), with early signs 
of neovascularization. For two weeks, the mononuclear cell population continues to infiltrate the 
ECM scaffold, including macrophages for apoptotic neutrophil removal, angiogenesis 
dramatically increases, and degradation of scaffold is advanced as newly formed host ECM is 
deposited. By day 14, a reduced mononuclear cell population consisting mostly of 
immunoregulatory macrophage phenotype (M2) resides and site-specific parenchymal cells appear 
to begin the final phase of constructive remodeling along with circulating, marrow derived 
progenitor cells. By day 35, there should be minimal to no scaffold present and a dense, highly 
organized connective tissue present (Brown, Ratner, et al. 2012, Badylak 2002, 2004, Brown, 
Londono, et al. 2012). 
Despite a multitude of publications investigating the use of synthetic and natural materials 
for adipose tissue engineering, there remains a clinical need to have an off-the-shelf biomaterial 
for adipose restoration. Recent advances in decellularization have provided researchers an 
alternative material to employ in all areas of tissue engineering. Ideally, decellularization is 
designed to remove the immunogenic material from donated biological sources while retaining as 
 13 
many constitutive components as possible. ECM can be derived from a specific tissue source to 
exploit its unique assortment of endogenous factors to restore its respective milieu. Many 
endogenous factors such as vascular endothelial growth factor, transforming growth factor (TGF) 
beta 1, basic fibroblast growth factor, placenta growth factor and insulin-like growth factor 1 
affecting angiogenesis have been identified in adipose tissues (Choi et al. 2014a). Decellularized 
adipose tissue (DAT) has gained significance in the tissue regeneration field as scaffold material 
in the form of hydrogels, sponges, injectable hydrated material, and fibers constructed from 
adipose ECM.  
Several groups have validated DAT hydrogel from human and porcine as a support 
structure for cellular activity in vitro (Sano et al. 2014, Choi et al. 2014b, Choi et al. 2011, Young 
et al. 2011, Uriel et al. 2008, Poon et al. 2013).  The investigation of porcine adipose ECM utilized 
freeze-thaw cycles along with trypsin/EDTA to decellularize porcine tissue. Resultant porcine 
derived biomaterial demonstrated DNA content 99.5% less than native tissue and successful 
cellular infiltration in vitro over 8 days. However, the absence of animal studies undermines its 
actual potential (Roehm, Hornberger, and Madihally 2016). Pepsin was utilized for digestion  to 
create an injectable hydrogel from dry milled human DAT; endogenous proteins like collagen I, 
III, and IV were present after processing (Young et al. 2011). Gelation of the hydrogel occurred 
with subcutaneous bolus injections in athymic mice. However, implants were excised 15 minutes 
later and further points in time were not investigated. In a later publication, this research was 
updated to include ASC-seeded scaffolds with or without transglutaminase (TG), an angiogenic 
cross-linker (Adam Young, Bajaj, and Christman 2014).  It was discovered that the addition of TG 
and ASCs significantly improved vascularization in vivo compared to the human DAT hydrogel. 
Oil red O staining of lipids within the scaffolds after 4 weeks in vivo also indicated superior 
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adipogenesis in human DAT hydrogel containing TG and ASCs (Adam Young, Bajaj, and 
Christman 2014).   
Several groups have investigated seeding ASCs with DAT as a therapy for stimulating 
natural adipose tissue restoration including the fabrication of an injectable microparticle 
formulation in saline for engineered fat graft evaluation. Human ASCs were combined with human 
DAT to study adipose tissue engineering implanted subcutaneously in nude rats for up to 8 weeks 
compared to human fat graft and hASC injection. Vessel density confirmed by IHC staining 
showed that human DAT-ASCs grafts at 4 and 8 weeks contained less blood vessels compared to 
the fresh human fat grafts. H&E staining also confirmed remodeling of fresh graft and surrounding 
tissue resembling new adipose formation (Wang, Johnson, et al. 2013). In a cell culture comparison 
study, ASCs were induced in adipogenic media for two weeks and seeded onto various scaffolds 
(type I collagen sponge, PGA, and hyaluronic acid) prior to implantation into athymic mice. 
Compared to ASCs seeded in normal culture media in various scaffolds, the area of newly 
generated adipose tissue was significantly increased in the induced ASCs group. However, within 
the induced ASC group, only the type I collagen sponge displayed noticeable amounts of 
adipogenesis after 8 weeks. Induced ASCs in PGA and hyaluronic acid gel displayed minimal 
adipocyte growth (Itoi et al. 2010). In summary, the results confirm that current investigations of 
composite scaffolds are not inductive towards adipose tissue formation with deficient angiogenic 
penetration (Itoi et al. 2010).  
As a strategy to increase clinical relevance, Han et al. assessed allogenic rat ASC-seeded 
DAT scaffolds implanted subcutaneously in an immunocompetent Wistar rat model. Cells were 
seeded 72 hours prior to implantation (Han et al. 2015). Compared to non-seeded scaffolds, 
significant remodeling into mature adipocytes was observed in the ASC-seeded groups at 8 and 12 
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weeks. Adipogenic marker expression in surrounding macrophages confirmed these results as well 
as correlated increases blood vessel diameter at 12 weeks. The scaffold platform investigated in 
this study provides invaluable preclinical data towards clinical trials (Han et al. 2015).  
Specific ECM and cellular parameters can be adjusted to influence cellular behavior. For 
example, the effect of DAT particle size and cell density on ASC proliferation and differentiation 
was assessed in a composite methacrylate chondroitin sulfate (MSC)-DAT hydrogel. At a cellular 
density of 2500 cells/l of MSC-DAT hydrogel, proliferation of human ASCs was significantly 
higher than using DAT of large particle size (~280 m) compared to the small particle size group 
(~40 m).  However, at an ASC concentration of 5000 cells/l of hydrogel, the small particle size 
group displayed a significantly outperformed all groups with the greatest amount of adipogenesis, 
identified by glycerol-3-phosphate dehydrogenase activity and laminin production (Brown et al. 
2015).    
In an attempt to enhance fat graft volume retention, FGF-2 was loaded into an injectable 
decellularized adipose matrix (mouse-derived tissue) to be investigated as a potential soft-tissue 
replacement for reconstructive surgery (Zhang et al. 2016). A 12-week animal study compared to 
performance of FGF-2-Loaded DAT to PBS hydrated DAT in the form of subcutaneous injections. 
Results indicated significantly more adipose neotissue formation and higher volume retention at 6 
weeks in the FGF-2 group. Adipocyte quantifications at 12 weeks for the FGF-2-loaded group 
were also comparable to endogenous mouse adipose (Zhang et al. 2016).  
The use of decellularized ECM from tissues other than adipose have also been examined 
for soft tissue repair.  For example, PLGA microspheres containing FGF-2 were combined with 
decellularized small intestinal submucosa (SIS) particulates and ASCs in an athymic mouse 
subcutaneous model for adipose tissue growth (Marra et al. 2008). Initially, ASCs were cultured 
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and allowed to proliferate on SIS particulate before injection. Following the SIS injection, mice 
received either 1 ng of free FGF-2, 1 ng dose of FGF-2 in PLGA microspheres, or no FGF-2. 
Blood vessel quantification was significantly higher in mice receiving FGF-2 microspheres (Marra 
et al. 2008).  
 
1.3.3 Naturally-Derived Materials 
Collagen and hyaluronic acid (HA) are two of the most common naturally-derived biomaterials 
for scaffolds examined in tissue engineering. The enzymatically degradable glycosaminoglycan, 
hyaluronic acid, consists of multiple repeating disaccharide units of N-acetyl-D-glucosamine and 
D-glucuronic acid. HA is a major component of the extracellular matrix due to its prominent role 
in cellular behavior, mechanical support, nutrient diffusion, high water retention and intrinsic 
swelling property. HA-based scaffolds are currently available on the market for various surgical 
procedures (Itoi et al. 2010, Stillaert et al. 2008, Cohen et al. 2013).  
The potential of HA as an off-the shelf biomaterial for adipose tissue growth has been 
studied by several research groups. Tan et al. developed an injectable thermosensitive HA gel that 
confirmed in situ gel formation after subcutaneous injection into athymic mice up to 5 days (Tan 
et al. 2009). However, HA undergoes rapid absorption in vivo (Hemmrich et al. , Okabe et al. 
2009). A composite device involving an HA-based (HYAFF11) pre-adipocyte seeded scaffold 
implanted in subcutaneous pockets of human volunteers, using a 1 cm median sub-umbilical skin 
incision, up to 16 weeks, has been reported (Stillaert et al. 2008). Histological analysis results 
indicated that the HA-based scaffold with and without preadipocyte seeding lacked evidence of 
any mature adipocytes at 16 weeks. In summary, the results confirm the current proposed 
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composite scaffolds are not inductive towards adipose tissue formation with deficient angiogenic 
infiltration (Itoi et al. 2010).  
Enhancing the adipogenic properties of hydrogels may be achieved by combining drugs or 
cytokines.  For example, Fan et al. attempted to improve adipose tissue formation in HA hydrogels 
through aqueous Diels-Alder chemistry (Fan et al. 2015). The HA hydrogel was functionalized for 
a sustained release of dexamethasone over a two-week time period. In vitro studies conveyed 
significant increases of the ASC population in groups containing the functionalized Dex-HA 
hydrogel compared HA gels after 14 days. The same mechanism of drug release was used in 
magnetic HA nanospheres capable of delivering dexamethasone controlled by an external 
magnetic field (Jia et al. 2015). In vitro ASC culture results confirmed an increase in cell viability 
and activity with magnetic HA nanospheres with Dex under a magnetic field. Controlled 
drug/biomolecule delivery continues to be an evolving asset in tissue restorative therapies.  
Collagen is a naturally-derived ECM protein that provides biodegradability, 
biocompatibility, and weak antigenicity. Several collagenous based biomaterials have been studied 
due to their favorable characteristics, long history of safety, and FDA-approval. One of the earliest 
studies of collagen and FGF-2 therapy reported the use of reconstituted basement membrane 
extracellular matrix, Matrigel™, to deliver FGF-2 subcutaneously in BALB/c nude mice at several 
concentrations (Kawaguchi et al. 1998). Experimental groups receiving Matrigel™ supplemented 
with FGF-2 at 10 ng/ml, 100 ng/ml, and 1000 ng/ml, observed neovascularization within 7 days, 
followed by migration of endogenous ASCs. A visible fat pad was observed between 1-2 weeks 
and was maintained up to 10 weeks (Kawaguchi et al. 1998). An alternative to free FGF-2 delivery 
has been investigated in gelatin microspheres containing 1 µg incorporated in the Matrigel™ 
scaffold along with ASCs (Kimura et al. 2003). Using a BALB/c nude mouse model, a significant 
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difference in adipose tissue formation was discovered using gelatin microsphere encapsulated 
FGF-2 compared to free FGF-2 in the collagen sponge subcutaneous implant. Additionally, the 
highest degree of adipose tissue was formed using 2.5 x 104 ASCs/cm2 of the implant site 
compared to 1.25 x 104 cell/cm2 and 5 x 103 cells/cm2 (Kimura et al. 2003).  
Matrigel™ was investigated with alginate microbeads containing fibroblast growth factor 
(FGF-1) to induce neovascularization and adipogenesis in a rat vascular pedicle model of adipose 
tissue engineering (material of interest deposited in silicone tube with vasculature wrapped in local 
fat pad) (Moya et al. 2010). Vessel density and area of adipose tissue was measured after 6 weeks. 
Compared to a bolus injection of FGF-1 and empty alginate microbeads, Matrigel™ containing 
2.5 µg/ml of FGF-1 in microbeads experienced higher rates of vessel density. However, no 
difference in adipose tissue formation was observed between the bolus injection group and FGF-
1 microbeads group at 2.5 µg/ml dose (Moya et al. 2010).  
Porous collagenous microbeads (CultiSphers; Sigma.) have been evaluated as an injectable 
cell delivery scaffold for ASCs (Rubin et al. 2007). In vitro studies using a spinner flask showed 
ASCs in culture attach and seed into microbeads at a high capacity. The ability to proliferate and 
differentiate was also confirmed with clear potential in culture up to 49 and 21 days, respectively 
(Rubin et al. 2007). An assessment of cell viability post-injection and tissue growth in vivo are the 
logical next steps to advance this technology for adipose tissue regeneration.  Since these early 
studies, there have been multiple in vivo studies examining collagen in adipose tissue engineering 
(Cherubino et al. 2016, Itoi et al. 2010, von Heimburg et al. 2001, Kimura et al. 2003, Vashi et al. 
2006). Overall, collagen-based scaffolds require ASC cell seeding or controlled release FGF-2 to 
promote new adipose tissue formation and vascularization.   
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While the majority of studies with collagen consisted of bovine collagen, salmon collagen 
has also been evaluated as a scaffold for its ligand protein interactions. This protein biomaterial 
was prepared with and without pioglitazone, a known inducer of adipogenesis via peroxisome 
proliferator-activated receptor- (PPAR) (Yazawa et al. 2015). Using a C3H/He/N mouse model, 
biomaterials were injected subcutaneously and analyzed at 1 week and 4 weeks. Histological 
results showed mature adipocyte growth substituting the pioglitazone collagen after 4 weeks 
compared to minimal tissue growth in the control group without pioglitazone.  
While scaffold performance of collagen and HA has been analyzed individually, the 
combined form of these natural biomaterials have implications on the future use of multi-
component scaffold. Collagen (type I, derived from bovine Achilles) and HA (derived from bovine 
vitreous humor) has been crosslinked to develop a three-dimensional scaffold that encourages 
adipose tissue development (Davidenko et al. 2010). Collagen-HA scaffolds were characterized, 
seeded with ASCs, and compared to collagen scaffolds. The results indicated that collagen-HA 
significantly increased gene expression of adipsin, an enzyme involved in lipid metabolism 
predominately in mature adipocytes (Lu et al. 2014), and noticeably higher levels of PPAR. The 
inclusion of HA in collagen scaffolds may aid adipogenesis by hastening cell-contacted growth 
arrest prior to adipogenic conversion (Davidenko et al. 2010). Preadipocytes seeded on collagen 
coated with elastin has also been recognized as a potential scaffold with the ability to encourage 
cell proliferation, infiltration, and adhesion (Keck et al. 2011b).  
Gelatin, a partially degraded product of collagen, contains amino acid sequences which can 
enhance cell attachment (Chang, Liao, and Chen 2013a). Gelatin has also been combined with 
hyaluronic acid as a complementary ingredient for cryogel scaffolds. Gelatin-HA cryogel scaffolds 
were seeded with porcine ASCs and implanted into the subcutaneous pocket of two separate 
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animal models: murine and porcine. Acellular cryogels were also implanted for comparison. The 
relative gene expression of adipocyte-specific genes (PPAR, LPL, aP2, and leptin) were 
significantly greater in the seeded gelatin-HA scaffolds than acellular scaffolds at weeks 2, 4, and 
8 in both animal models. It is important to note that both seeded and acellular scaffolds exhibited 
positive CD31 staining at 8 weeks showing how adequate porosity sufficiently provided space for 
vascularization in the acellular scaffold implants, a characteristic many other acellular scaffolds 
failed to demonstrate (Chang, Liao, and Chen 2013b). 
Chitosan (CS) is another biodegradable natural material currently being used in tissue 
engineering applications (Wang, Cao, et al. 2013b, Tan, Rubin, and Marra 2010, Wang, Cao, et al. 
2013a).  The biocompatible characteristics of cell adhesion and growth were determined using 
crosslinked CS with poly(L-glutamic acid) to mimic natural ECM (Wang, Cao, et al. 2013a). A 
porous scaffold was developed via lyophilization for evaluation of engineered adipose tissue in 
severe combined immunodeficiency (SCID) mice. Acellular and ASC-seeded scaffolds were 
implanted. After 6 weeks, scaffolds remained intact with vascularization reported in the cell-
seeded scaffolds. Cell-seeded poly(L-glutamic acid)/CS scaffolds retained 90% volume and Oil 
Red O staining indicated adipose tissue formation within the implant (Wang, Cao, et al. 2013a). 
Minimal adipose tissue was formed within acellular implants. CS has also been crosslinked with 
HA to produce an injectable hydrogel scaffold capable of delivering dexamethasone for adipose 
tissue growth (Sun et al. 2013). Results in ASC culture revealed dexamethasone as an important 
factor in hydrogel performance with increased proliferation and cell adhesion.     
Silk is another widely examined biomaterial for soft tissue repair produced by members of 
the arachnid animal class and cultured silkworms (Vepari & Kaplan 2007). Silk is a naturally 
occurring biocompatible protein with tunable mechanical strength, adjustable degradation rate, and 
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low inflammatory and immunogenic responses (Abbott et al. 2016, Bellas et al. 2015). In reference 
to the application of silk to soft tissue regeneration, Bellas et al. evaluated silk at three 
concentrations in the form of an injectable foam scaffold. Silk foams supported in vitro ASC 
survival and migration over a 10-day period. Subcutaneous injections of silk scaffolds in Sprague-
Dawley rats demonstrated significant degradation after 90 days with new tissue formation, and 
cell-seeding ASCs into the silk scaffold may have contributed to new adipose tissue growth in 
vivo. 
Overall, the use of natural-biomaterial based therapies has led to considerably positive 
results both in vitro and in vivo. The use of ASCs for in vivo injection studies showed significance 
for several research groups. Additional comparison studies of natural biomaterials containing 
ASCs with various therapeutic agents in vivo will identify the ideal combination of components. 
 
1.4 DRUG DELIVERY SYSTEMS FOR ADIPOSE TISSUE ENGINEERING 
An increasingly widespread trend for adipose restoration has been to incorporate additional 
biomolecules or biological factors with scaffold material to facilitate new adipose tissue formation, 
thus creating composite biomaterials. Basic fibroblast growth factor (FGF-2) (Zhang et al. 2016, 
Kimura et al. 2003, Kawaguchi et al. 1998, Vashi et al. 2006), fibroblast growth factor (FGF-1) 
(Moya et al. 2010), dexamethasone (Fan et al. 2015, Kelmendi-Doko et al. 2017, Sun et al. 2013, 
Rubin et al. 2009a, Jia et al. 2015), adipose-derived stem cells (ASCs) (Wang, Johnson, et al. 2013, 
Cheung et al. 2014a, Brown et al. 2015), pioglitazone (Yazawa et al. 2015), insulin (Masuda, 
Furue, and Matsuda 2004, Hong et al. 2010b, Rubin et al. 2009a), and insulin-like growth factor I 
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(IGF-1) (Masuda, Furue, and Matsuda 2004) are among several additive components that have 
been evaluated in vitro/in vivo. Several methods of encapsulation have been used to localize the 
delivery of the therapeutic agents. Table 1 contains a comprehensive list of therapeutic agents, 
encapsulation strategies used, and the expected biological responses from their use. The effects of 
these therapeutic agents on preadipocyte differentiation and adipose tissue have been described 
further in illustration (Figure 3). FGF-2 is a member of fibroblast growth factors and most widely 
used angiogenic factor to stimulate blood vessel infiltration and subsequent de novo adipogenesis 
(Lu et al. 2014, Zhang et al. 2016, Jiang et al. 2015). Insulin binds to IGF-1 receptors to mimic 
most of the biological effects of IGF-1 (Lu et al. 2014). IGF-1 and insulin activates 
phosphorylation of cAMP response element binding protein (CREB) in ASCs to induce 
differentiation while also regulating triglyceride synthesis through sterol regulatory element-
binding protein-1c (SREBP1c) (Lu et al. 2014, Widberg et al. 2009). Vascular endothelial growth 
factor (VEGF) is a major regulator of vasculogenesis and angiogenesis, serving as a mitogen for 
vascular endothelial cells (EC) along with several other roles (Chung et al. 2012a).  Pioglitazone 
hydrochloride (P-zone) promotes peroxisome proliferator receptor- (PPAR-) mRNA expression 
in ASCs, a critical step in adipogenesis, as well as increases mRNA levels of insulin responsive 
glucose transporter (GLUT4) (Yazawa et al. 2015, Lu et al. 2014). It is believed that FGF-1 
increases expression of PPAR- and members of the CCAAT enhancer binding protein (C/EBP) 
family of transcription factors to prime ASCs for proliferation and differentiation (Hutley et al. 
2004, Widberg et al. 2009). Dexamethasone (Dex) targets activating transcription factor 4 (ATF4) 
to initiate adipocyte differentiation in ASCs (Widberg et al. 2009). Direct comparisons of these 
additives in the appropriate animal model as well as their feasibility for commercial production 
are imperative for developing a clinically relevant adipogenic biomaterial. 
 23 
Table 1. Therapeutic Agents for Adipose Tissue Defects  
Drugs/Biomolecules Methods of Delivery Cellular Response References 
    
Dexamethasone double-
emulsion/solvent 
extraction (PLGA 
microspheres) 
Down-regulate 
expression of 
preadipocyte factor-1 
(pref-1) 
(Fan et al. 2015, 
Kelmendi-Doko et 
al. 2017, Sun et al. 
2013, Jia et al. 2015, 
Rubin et al. 2009a)    
 
Insulin double-
emulsion/solvent 
extraction 
(microspheres); 
photocured to gelatin 
microspheres 
Stimulates glucose 
uptake, lipogenesis,  
and inhibits lipolysis 
through IGF-1 
(Rubin et al. 2009a, 
Masuda, Furue, and 
Matsuda 2004, Tan, 
Rubin, and Marra 
2010, Kim et al. 
2016)    
 
Insulin-like growth 
factor-1 
(IGF-1) 
photocured to gelatin 
microspheres 
Activates AKT and 
MAPK signaling  
pathways 
(Masuda, Furue, and 
Matsuda 2004, Kim 
et al. 2016)    
 
Basic fibroblast 
growth factor 
(FGF-2) 
mixed heparinized 
protein; 
photocured to gelatin 
microspheres;  
hydrogel supplement;  
double emulsion 
(PLGA 
microspheres) 
Upregulates mitotic 
genes 
(Masuda, Furue, and 
Matsuda 2004, 
Zhang et al. 2016, 
Kimura et al. 2003, 
Kawaguchi et al. 
1998) 
   
 
Pioglitazone 
hydrochloride  
(P-zone) 
saline gel mixture Ligand for PPAR-𝛾; 
increase GLUT4  
expression  
(Yazawa et al. 2015) 
   
 
Vascular endothelial 
growth factor 
(VEGF) 
double-
emulsion/solvent 
extraction (PLGA 
microspheres) 
Mitogen for vascular 
EC; increase EC 
migration, regulate 
microvascular 
permeability and 
vasodilation   
(Chung et al. 2012a, 
Zhu et al. 2010, 
Topcu et al. 2012) 
   
 
Fibroblast growth 
factor  
(FGF-1) 
heparin incubation Increase PPAR-𝛾 
expression 
(Moya et al. 2010, 
Widberg et al. 2009) 
 
 24 
The effects of therapeutic agents on ASCs, vascular cells, and adipocytes have been exploited in 
numerous studies to enhance the functional behavior of biomaterials and autologous fat grafts. 
 
Figure 3. Effects of therapeutic agents on ASC differentiation 
1.4.1 Polymeric Microspheres 
Polymers such as poly (lactic-co-glycolic acid) (PLGA) can be used to encapsulate drugs or 
proteins using an oil-in-water technique in which the polymer is dissolved into an organic phase 
(oil) that is emulsified with a surfactant or stabilizer (water). Hydrophobic drugs are added directly 
to the oil phase, whereas hydrophilic drugs are first emulsified with the polymer solution prior to 
formation of polymer droplets. High intensity sonication bursts facilitate the formation of small 
polymer droplets. The resulting emulsion is added to an aqueous phase and stirred for several 
hours, which allows the solvent to evaporate. The double emulsion technique results in 
microspheres with a more controlled release and reduces the burst drug release effect observed in 
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the studies of single walled microspheres. Double walled microspheres can be prepared by 
incorporating a previously sonicated PLGA/drug mixture in solvent into another dissolved 
polymer solution such as PLA in solvent and administering high intensity sonication to create 
droplets around the previously formed polymer droplets (McCall and Sirianni 2013, Pekarek, 
Jacob, and Mathiowitz 1994). The diameter of drug encapsulated microspheres generally range 
from ~1-1000 m which can be suspended in a gel or solution for a localized controlled delivery 
of the drug directly to the intended targeted tissue while avoiding systemic side effects caused by 
oral administration and possibilities of user error which include as under- and overdosing.  
Researchers have utilized microspheres to encapsulate growth factors and pharmaceuticals 
aiming to develop clinically relevant tissue engineering therapies (Rubin et al. 2009a, Topcu et al. 
2012, Zhang et al. 2016, Chung et al. 2012a). VEGF was encapsulated in calcium alginate 
microspheres to create a controlled release system and was evaluated in a Wistar rat model 
receiving fat grafts  (Topcu et al. 2012). Rats in groups 1 and 2 received microspheres (MS) 
containing 2 µg/0.1 mL VEGF subdermally 21 days prior to fat grafting and mixed within fat graft, 
respectively. After 90 days, the fat graft control group lost over 50% of mass while groups 
receiving VEGF calcium alginate MS showed an increase in weight over 25%. Microvascular 
density results were also significantly higher in the VEGF microsphere pre-injection group and 
VEGF MS mixed with fat graft group. VEGF has also been encapsulated in poly(lactic-co-
glycolic) (PLGA) MS as a potential therapy for transferred human lipoaspirate (Chung et al. 
2012a). Human lipoaspirate with and without PLGA VEGF MS were injected into the flanks of 
athymic mice and evaluated up to 6 weeks for vascularization and tissue survival. Significantly 
higher mean masses and volumes in the VEGF-loaded microsphere group were seen at 6 weeks. 
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Additionally, there was IHC staining qualitatively displayed increased vascularization in the 
VEGF MS group at 6 weeks compared to 3 weeks results.  
Rubin et al. utilized PLGA MS to encapsulate two adipogenic factors, dexamethasone 
(Dex) and insulin, as a method to stimulate adipogenesis in ASCs. Results showed that ASCs 
treated with dexamethasone and insulin microspheres contained a significantly higher number of 
adipocytes compared to control groups (Rubin et al. 2009a). More recently, Doko et. al utilized 
this same microsphere delivery system with encapsulated adipogenic factors to increase retention 
of transplanted adipose tissue (Kelmendi-Doko et al. 2014). Dex and insulin were loaded into 
PLGA MS and mixed at various doses with human fat grafts to be injected subcutaneously into 
the dorsal aspect of athymic mice. After 5 weeks, volume analysis showed increased graft retention 
with use of Dex-loaded PLGA MS. Blood vessel density was also increased with the use of the 
adipogenic encapsulated MS. Doko et al. extended the investigation of Dex MS in a double-walled 
(DW) formulation mixed into human fat grafts (Kelmendi-Doko et al. 2017). Control human fat 
grafts explanted from athymic mice after 6 months demonstrated significant volume loss (i.e. 
~90%) while groups containing the DW Dex MS resulted in a mean volume loss of ~ 33%, thus 
demonstrating the beneficial effects of a slow, controlled release delivery system.  
In another study, Masuda, et al. proposed the co-release of insulin with additional 
encapsulated drugs from styrenated, gelatin-based microspheres (SGM) (Masuda, Furue, and 
Matsuda 2004). Insulin, IGF-1, and FGF-2 were encapsulated to develop a drug delivery system 
that induces neovascularization and migration of endogenous ASCs, followed by proliferation and 
differentiation into adipocytes. Subcutaneous lesion injections of SGMs in Wistar rats were 
evaluated after 6 weeks. The total lipid content extracted from the experimental group receiving 
FGF-2, insulin, and IGF-1 SGMs were significantly higher than groups receiving insulin SMGs 
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alone, IGF-1 SGMs alone, and insulin/IGF-1 combined SGMs (Masuda, Furue, and Matsuda 
2004). 
1.4.2 Hydrogels  
Hydrogels are three-dimensional networks of hydrophilic polymers crosslinked by covalent bonds, 
physical intramolecular, and/or intermolecular attractions (El-Sherbiny & Yacoub 2013; Van 
Tomme et al. 2008). Hydrogels can absorb large amounts of water or biological fluids without 
dissolving while resembling the characteristic of soft living tissue. The soft and hydrophilic nature 
of hydrogels make them particularly suitable as a drug delivery system or as a cell-entrapping 
scaffold for tissue engineering (Toh & Loh 2014). Hydrogels designed for drug delivery typically 
do not contain chemical crosslinking agents due to incompatibility with fragile molecules such as 
pharmaceutical proteins and living cells (Van Tomme et al. 2008). Injectable hydrogel drug 
delivery systems are of particular interest as a non-invasive therapy for their ability to form in situ, 
at the site of injection, without the aid of potentially toxic or denaturing crosslinking agents (Van 
Tomme et al. 2008). Hydrogels comprised of ECM proteins have the ability to gel spontaneously 
under physiological conditions while delivering pharmaceutical agents for tissue regeneration.    
1.4.3 Dexamethasone 
Dexamethasone is an FDA approved synthetic adrenocortical steroid in the form of a white, 
odorless, crystalline powder that is stable at room temperature. Glucocorticoids (GCs), naturally 
occurring and synthetic, are readily absorbed from the gastrointestinal tract. The synthetic analog, 
Dex, is primarily used for their anti-inflammatory effects in disorders of many organ systems. As 
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an adipogenic factor, Dex and other GCs are required for the full differentiation of adipose 
precursors and for the maintenance of key genes in glucose and lipid metabolism in cultured 
adipocytes and adipose tissue. As a result of its anti-inflammatory nature, Dex decreases the 
expression of inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor alpha 
that are mainly expressed in non-adipocyte fraction in human adipose tissue (Lee and Fried 2014). 
Side effects of administering Dex orally include anxiety, irritability, mental depression, mood 
changes, blurred vision, decrease in urine volume, dizziness, shortness of breath, and weight gain. 
In order to avoid the side effects of oral administration of drugs such as Dex, localized drug 
delivery and polymer microsphere encapsulation has allowed for a more advanced, controlled 
administration of therapies. 
1.5 PROJECT OBJECTIVES 
1.5.1 Design, develop, and characterize a composite adipose derived delivery system 
(CADDS) 
The first objective was to confirm suitability of the adECM to be used as a biomaterial as well as 
the dexamethasone microsphere delivery system. Specifically, it was critical to ensure the removal 
of immunogenic components such as residual lipids/DNA while preserving the fundamental ECM 
structure. Characterization, including cumulative dexamethasone release and homogeneous 
distribution of the microspheres, was a vital step in the development of a unique and reproducible 
drug delivery system. We hypothesized that if ECM from human adipose tissue can aid in adipose 
tissue restoration, the ECM must be decellularized to prevent adverse reactions as a biomaterial. 
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1.5.2 Determine the bioactivity and adipogenic potential of CADDS 
The objective of this aim was to evaluate the biological potential of the hydrogel with cell culture 
studies. The in vitro assessment of biocompatibility, adipogenesis, and bioactivity was a 
comprehensive step to determine efficacy of the composite adipose-derived delivery system 
(CADDS) prior to examination in an animal model. We hypothesized that human adipose derived 
stem cells (hASCs) cultured with CADDS will demonstrate bioactivity in vitro and respond with 
an increased degree of adipogenesis. 
1.5.3 Evaluate the in vivo response and volume retention of CADDS implanted in an 
immunocompetent animal model 
The objective of this aim was to compare the administration of hydrated adipose derived scaffolds 
to CADDS by tracking volume retention and examining histological sections at the end of the 
study. Explant tissue sections were compared and evaluated for structure and integration with the 
surrounding tissue. We hypothesized that if CADDS is implanted in an immunocompetent small 
animal model, CADDS will result in higher volume retention in groups containing dexamethasone 
encapsulated microspheres with a healthy adipose architecture.  
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2.0  DESIGN, DEVELOP, AND CHARACTERIZE A COMPOSITE ADIPOSE 
DERIVED DELIVERY SYSTEM (CADDS)  
2.1 INTRODUCTION 
The current limitations surrounding adipose tissue restoration involve rapid resorption of natural 
biopolymers, lack of adipose stimulation by synthetic biomaterials, and volume loss of autologous 
adipose grafts (Nahabedian 2015; Hong et al. 2016; Patrick 2001; Boccaccini et al. 2005; 
Davidenko et al. 2010; Hemmrich & von Heimburg 2006). When normal appearance is 
compromised by chronic disease, trauma, or tumor resection, the options for adipose tissue 
restoration either have a vascularized or non-vascularized approach. The field of tissue engineering 
has begun to address challenges within the category of non-vascularized approaches using 
strategies that engineer tissue tailored to a specific site of injury (Keck et al. 2011; Choi et al. 
2010). Additionally, researchers have also been incorporating biological and growth factors to 
enhance these strategies. The objective of this study was to characterize the components of an 
adipose-derived hydrogel containing adipogenic factors as a potential biomaterial to restore 
volume in adipose defects.  
Scaffolds and hydrogels comprised of extracellular matrices have been used clinically for 
over a decade and have shown moderate success in adipose tissue engineering (Hemmrich & von 
Heimburg 2006; Choi et al. 2011; Yu et al. 2013; Cheung et al. 2014; Choi et al. 2014).  Adipose 
extracellular matrix isolated through decellularization can contain specific components such as 
collagen, elastin, sGAGs, and laminin that provide specific instructive biological cues for growth, 
migration, and differentiation to residing cells in situ (Yu et al. 2013; Choi et al. 2014). The 
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following study combines the latest advancements in adipose tissue engineering to develop an 
injectable hydrogel scaffold derived from discarded adipose tissue enhanced with dexamethasone-
encapsulated microspheres for the controlled delivery. Discarded adipose tissue was decellularized 
and evaluated for suitability as a biomaterial. Dexamethasone encapsulated microspheres were 
fabricated in single- and double-walled formulations and fully characterized as well.  This 
knowledge was critical for the development of further studies in vitro involving adipose derived 
stem cells.  
2.2 METHODS 
2.2.1 Adipose Tissue Processing and Decellularization 
Adipose tissue samples were collected as discarded biological material from female patients (non-
diabetic, age 21 to 60) undergoing elective abdominoplasty within the University of Pittsburgh 
Medical Center system as approved by the institution review board. The decellularization process 
for adipose tissue has been established in the laboratory and optimized for reproducibility (Brown 
et al. 2011). The process reduces human adipose tissue matrix to decellularized extracellular in 
approximately seven days (Figure 4). Briefly, mechanical processing using a commercial meat 
grinder breaks the fibrous tissue apart and creates a homogeneous mixture. Alcohol and salt 
solution rinses were used to extract triglycerides and cellular material from the matrix. After 
disinfection via low concentrate peracetic acid, 10x PBS rinsing (phosphate buffer solution) 
balances the pH before flash freezing to prepare the matrix for lyophilization. The final step results 
in a dry decellularized adipose ECM, seen in Figure 5a.  
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Figure 4. Decellularization Process of Discarded Adipose Tissue     
 
 
Figure 5. A) Dry AdECM after lyophilization, B) Milling process of AdECM, C) Powder-form AdECM 
2.2.2 Decellularized matrix characterization 
Decellularized matrix were fixed and embedded in paraffin and/or optimal cutting temperature 
compound to be prepared for tissue sections. Tissue sections were stained for collagens, (types 1, 
3, 4, and 6), heparan sulfate proteoglycan (HSPG), and nidogen along with hematoxylin and eosin 
(H&E) and Oil Red O. Polyclonal anti-mammal collagen (types 1, 3, 4, and 6), nidogen, and HSPG 
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antibodies were purchased from abcam (Cambridge, MA, USA) and Life Technologies (Grand 
Island, NY). These specific proteins were chosen for staining due to their influence on cell 
guidance and migration, support, binding growth factors, and attachment within the ECM.  
Total DNA content was also assessed using a Quant-IT PicoGreen double-stranded DNA 
(dsDNA) assay kit (Invitrogen, Carlsbad, CA). Samples will be proteinase K-digested for up to 1 
h (60 mAU/ml, 50 °C), then heated at 95° for 5 min. Samples were centrifuged and the supernatant 
was added to 1X TE buffer for incubated with fluorescent PicoGreen reagent for 30 minutes. 
Fluorescence was measured using an Infinite® 200 Pro microplate reader (TECAN, Inc.) with 
excitation wavelength of 480 nm and emission wavelength of 520 nm. dsDNA was quantified by 
relating sample absorbance to the absorbance measured for standards of known DNA 
concentration. 
Residual lipid content of the decellularized ECM was assessed using an AdipoRed Reagent 
Assay (Lonza, Walkersville, MD). According to manufacturer’s instructions, in a 24-well plate, 
10 mg of decellularized ECM (n=6) per were compared to the same amount of adipose tissue (n=6) 
per well by mixing the samples with 1 ml of phosphate buffer solution and 30 l AdipoRed™. 
2.2.3 Hydrogel formation and characterization 
A Wiley Mill was used to break down the lyophilized adipose ECM into a powder like substance 
as seen in Figure 5b and Figure 5c. Next, the ECM was digested by porcine solution at 0.1 M 
hydrochloric acid (HCl). After two days of digestion, 1 M sodium hydroxide (NaOH) was added 
dropwise to slowly raise the pH to about 7.4. The adipose hydrogel formed after the solution was 
raised to physiological temperature of 37 °C. Scanning electron microscopy (SEM) was used to 
visualize the microstructure of the hydrogel. The hydrogels were fixed in an aqueous solution of 
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2% glutaraldehyde and 4% paraformaldehyde followed by dehydration with graded series of 
ethanol (30-100%). Dehydrated gels were critical point dried using CO2 and gold coat sputtered to 
prepare for clear imaging under SEM. Hydrogel degradation was observed under physiological 
conditions in 1X PBS (ThermoFisher Scientific, Waltham, MA) and collagenase/dispase buffer 
solution (1 mg/ml, Millipore Sigma, St. Louis, MO).  
2.2.4 Dexamethasone microsphere encapsulation 
Single emulsion/solvent extraction protocols established by the laboratory was used to fabricate 
dexamethasone encapsulated in single walled microspheres  (SW Dex MS) (Rubin et al. 2009; 
Chung et al. 2012). Poly (lactic-co-glycolic acid) (PLGA) (75:25) was dissolved in methylene 
chloride (MC). Dexamethasone disodium phosphate (Dex) was dissolved in methanol and added 
to the polymer solution. A vortex was used to mix the solution for at least 60 seconds. The mixed 
solution was added dropwise to a 2% poly (vinyl alcohol) (PVA) solution to extract solvent under 
magnetic stirring. After 3 hours, the MC solvent evaporates leaving behind microspheres to be 
collected by centrifugation. Lastly, the microspheres were frozen in deionized water (DI) with 
liquid nitrogen and lyophilized to remove all water content. Double-walled dexamethasone 
microspheres (DW Dex MS) were fabricated using the following protocol. PLGA (75:25) was 
dissolved in MC to produce a 10% polymer solution. Dex dissolved methanol was added to the 
polymer in a glass vial and placed under vortex for about a minute for the first emulsion. In a 
separate vial, polylactic acid (PLA) (50:50) was dissolved in MC to produce a 10% PLA solution. 
The PLA solution was then added to the PLGA-Dex emulsion to be placed under vortex for the 
second emulsion. Drops of the final solution were added to a 1% PVA solution under magnetic 
stirring which continues for about 3 hours to allow the MC solvent to evaporate. Morphology and 
 35 
size of the Dex MS were determined along with the adipose ECM hydrogel using a scanning 
electron microscope (JSM-6335F).  
2.2.5 In vitro release studies 
The encapsulation efficiency was determined using a UV-Vis Spectrometer. Dimethyl sulfoxide 
was used to quickly dissolve the PLGA causing the coating to release the encapsulated Dex from 
the MS. After balancing the pH, small diluted portions were measured with the spectrometer set 
at 242 nm absorbance wavelength. After comparing the absorbance to a standard curve, the 
correlated amount of Dex was divided by the known amount of Dex used in the emulsion protocol 
to calculate the encapsulation efficiency.  
Spectrophotometry was also used to determine the release of Dex from single and double-
walled MS. An in vitro drug release study was conducted by placing 5 mg of Dex MS (DW or 
SW) into a 1.5 ml Eppendorf tube containing 1 ml of 1X PBS. Tubes (n=5) were kept in an 
incubator at 37 °C between readings by the spectrometer. Readings were taken every 2-3 days and 
a fresh ml of 1X PBS will be replaced each time. 
 
2.2.6 Statistical analysis 
All quantitative data is presented as a mean ± standard error of the mean. Differences between the 
AdECM, human adipose tissue, and porcine dermis ECM were calculated for statistical 
significance by one-way analysis of variance (ANOVA) using GraphPad Prism 6. (GraphPad 
Software, Inc.). Differences are considered significant if p < 0.05. 
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2.3 RESULTS 
2.3.1 Decellularized matrix and CADDS microstructure  
AdECM microstructure and composition were evaluated in multiple ways. In Figures 6a and 6b, 
the scanning electron microscopic images show the morphological and structural properties of 
AdECM (100X magnification) and the CADDS with SW Dex MS (170X magnification), 
respectively. SW Dex MS examined by SEM range from 70-125 m in diameter. Both matrices 
share the characteristics of porosity, microstructural build, and fiber organization.  
 
Figure 6. SEM imaging of A) AdECM, B) Composite adipose derived delivery system (CADDS) 
2.3.2 AdECM histology characterization  
H&E staining of AdECM histological sections display a lack of nuclei stains (Figure 7) and DNA 
quantification analysis resulted in less than 4 ng of DNA per mg of AdECM (Figure 8). These 
characteristics are indicative of a properly decellularized matrix. Immunohistochemistry staining 
of AdECM sections show that constitutive proteins, laminin, nidogen, HSPG, Figure 9A-F, and 
Collagen (I, III, IV, and VI), Figure 10 and 11, were retained post decellularization.  
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Figure 7. H&E stain of AdECM 
 
 
Figure 8. Quantification of DNA content in four batches of AdECM 
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Figure 9. IHC staining of tissue sections for: Heparin sulfate proteoglycan (HSPG), (A) HAT, (B) AdECM; 
Laminin, (C) HAT, (D) AdECM; Nidogen, (E) HAT, (F) AdECM (100 µm scale bar). 
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Figure 10. IHC stains of tissue sections (A) Collagen 1, Human Adipose Tissue (HAT), (B) Collagen 3, Human 
Adipose Tissue, (C) Collagen 1, AdECM, (D) Collagen 3, AdECM 
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Figure 11. IHC stains of tissue sections (A) Collagen 4, Human Adipose Tissue (HAT), (B) Collagen 4, Human 
Adipose Tissue, (C) Collagen 6, AdECM, (D) Collagen 6, AdECM 
2.3.3 AdECM composition analysis 
The decellularizaton process removed a significant amount of cellular and lipid content reducing 
the human adipose tissue to a protein-enriched extracellular matrix. AdECM lipid content was 
comparable to commercial dermis ECM, significantly lower than human adipose (Figure 12). 
DMMB assay measured the remaining sGAGs to be approximately 100 ug/ml in the AdECM 
sample, compared to 50 ug/ml in the dermis ECM, and 9 ug/ml in the HAT sample (Figure 13).  
Total protein content measured by Pierce BCA assay reported significantly higher amounts of 
protein in the AdECM group compared to dermis material (Figure 14). 
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Figure 12. Quantification of lipid content in human adipose tissue, commercial dermis ECM, and AdECM 
 
 
Figure 13. Quantification of sGAG content in human adipose tissue, commercial dermis, and AdECM 
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Figure 14. Quantification of protein in 5 mg sample of human adipose, commercial dermis matrix, and 
AdECM 
2.3.4 SW and DW Dex MS characterization 
In vitro dexamethasone release from DW and SW MS were monitored for at least 50 days. Figure 
15 shows that within the first week of Dex release from SW MS, a large burst effect caused 
approximately 50% of the encapsulated drug to be released compared to a more controlled 50% 
release of drug after about 120 days from the DW MS containing the additional coating of PLA. 
Average size of the microspheres were determined by SEM with SW average diameter to be ~50 
µm (Figure 16A) and DW average diameter at ~90 µm (Figure 16B). 
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Figure 15. Cumulative in vitro release of dexamethasone SW and DW Dex MS 
 
  
Figure 16. Scanning electron microscopy images of (A) SW Dex MS and (B) DW Dex MS 
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acellular adipose matrix can provide constitutive cues, biochemical milieu, and sufficient structural 
scaffolding to promote precursor adipocyte infiltration while influencing adipose tissue restoration 
and remodeling in situ (Brown et al. 2011; Brown et al. 2010). With the addition of biocompatible 
polymers, cells, or growth factors, matrices can be enhanced to form a composite for further 
stimulation towards tissue restoration. An established adipose ECM extraction method was 
implemented to develop an acellular, protein-enriched, biologically active matrix and hydrogel as 
a delivery vehicle of stable, adipogenic factors as an off-the-shelf therapy for adipose tissue 
engineering.   
Several important characteristics need to be established when developing an adipogenic 
biomaterial from biological tissue. Initially, decellularization can be seen as a deciding factor with 
recent findings demonstrating that host response to cell remnants and amount of DNA in scaffold 
material can significantly alter tissue remodeling (Keane et al. 2012). More specifically, 
researchers have established a criterion for complete decelluarization such as lack of visible nuclei 
per H&E/DAPI stain, less than 50 ng of DNA per mg of dry weight matrix, and lengths of DNA 
have less than 200 base pairs (Londono & Badylak 2015). Consequences of ineffective 
decellularization ultimately can cause an immunological host response that hinders recruitment of 
cells and a cascade of biological signals that facilitate functional tissue repair and constructive 
remodeling. Therefore, the adECM obtained for the study was thoroughly evaluated for cellular 
and DNA content. 
As a hydrogel delivery system, the adECM is easy to manipulate and administer as a 
minimally invasive, off-the-shelf, injectable scaffold for adipose tissue engineering. Post-
implantation the collagen-based hydrogel forms into a solid gel with similar composition as 
adipose tissue at physiological conditions. Some advantages of this three-dimensional scaffold 
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include network of connecting pores, mass transport properties, and mechanical integrity for tissue 
formation. With the addition of Dex MS to the scaffold, the composite becomes a highly 
adipogenic specifically targeting precursor adipocytes to form new adipose tissue as demonstrated 
by the in vitro testing.  
Specific ECM elements with its own complex composition and concentration of chemical 
constituents known to regulate numerous cell processes, including attachment, survival, migration, 
proliferation, and differentiation (Young et al. 2011). The adipose derived matrix from the study 
retained its fundamental essential proteins namely collagen I, collagen III, collagen IV, and 
collagen VI in addition to nidogen, HSPG, and laminin. Each component plays an essential role in 
adipose development and homeostasis. Specifically, type I and type VI collagen provide structural 
support. Extracellular laminin form networks with collagen fibers and provide attachment points 
for integrins anchored in the adipocyte membrane. Similar to paracrine signals, integrins transduce 
cues from the extracellular matrix to regulate gene expression and function (Pope et al. 2016). 
Basal laminae of the adipose matrix consists of laminin (principal structural protein), HSPG, and 
type IV collagen. The basal laminae provides high affinity binding sites for other components of 
the ECM and for cell surface receptors (Teti 1992). By securing the presence of physiologically 
relevant matrix proteins in the composite delivery system, the host’s implant site receives the 
fundamental cues familiar with adipose tissue regeneration and homeostasis.  
2.5 CONCLUSION 
The research in this investigation has led to the development of a composite adipose derived 
delivery system for dexamethasone as an adipogenic factor in tissue engineering. Decellularization 
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of human adipose tissue was effective to produce an acellular biocompatible scaffold system while 
retaining essential proteins. Overall, the investigation introduces a unique combinations of tissue 
engineering strategies as a potential therapy to encourage adipogenesis and restore tissue function. 
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3.0  BIOACTIVITY AND ADIPOGENIC POTENTIAL OF THE COMPOSITE 
ADIPOSE DERIVED DELIVERY SYSTEM 
3.1 INTRODUCTION 
Human preadipocytes were first isolated over forty years ago and it was only ten years ago that 
their multi-lineage potential was discovered (Minteer et al. 2015). Since then, many biological 
properties of ASCs have been characterized utilizing in vitro and vivo studies (Patrick et al. 2002; 
Philips et al. 2012b; Otto & Lane 2005; Philips et al. 2014). As a result of their exquisite plasticity, 
human ASCs are known to have the ability to differentiate into numerous cell lineages including 
adipogenic, osteogenic, cardiomyogenic, neurogenic, myogenic, and chrondrogenic cell types. 
Additionally, numerous studies have demonstrated that ASCs express/secrete multiple growth 
factors including IGF, HCF, VEGF, and TGF-β1 (Widberg et al. 2009). In consideration of these 
biological characteristics, adipose tissue has recently proven to be an invaluable stem cell source 
for clinical application in tissue engineering instead of its previous role as a discarded and 
unwanted tissue. ASCs have also been established as a valuable tool to evaluate the adipogenicity 
of biomaterials and drug delivery techniques. As previously mentioned, glucocorticoids such as  
Dex are required for the full differentiation of adipose precursors and for the maintenance of key 
genes in glucose and lipid metabolism in cultured adipocytes and adipose tissue.  
We hypothesized that hASCs in contact with CADDS differentiate at a higher rate due to 
the constitutive protein interaction and Dex release from polymer microspheres. In order to assess 
the adipogenic potential of the CADDS material, in vitro experiments were conducted to evaluate 
the interaction of differentiating hASCs on CADDS and bioactivity of Dex MS.  
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3.2 METHODS 
3.2.1 Isolation of human ASCs (hASCs) 
Human ASC isolation was conducted as previously reported. This study was conducted in 
accordance with the regulations of the Human Studies Committee of the University of Pittsburgh.  
Tissue collection was performed according to a protocol approved by the University of Pittsburgh 
Institutional Review Board. ASCs were isolated from fresh human abdominal adipose tissue 
harvested during elective surgery. Human adipose tissue was minced in Hank’s Balanced Salt 
Solution containing 1 mg/ml collagenase and 3.5% fatty acid free BSA. Tubes containing minced 
tissue shaken and submerged in 37 C water bath. Once the solution appears homogenous, it is 
filtered with double layer gauze into a sterile tube. Following centrifugation at 1000 rpm for 10 
minutes, the supernatant and fatty layer is aspirated leaving behind a pellet of cells. Pellet is 
resuspended in erythrocyte lysis buffer and centrifuged again. Next, supernatant of lysis buffer is 
aspirated leaving behind a pellet to resuspend in ASC expansion/growth media and plate in T-75 
flask. After 4-6 hours in incubator (37 C and 5% CO2), cells have attached to culture plate. Finally, 
cells are washed 3 times with sterile 1X PBS and fresh ASC growth media is added to begin 
feeding. Rat ASCs were expanded on T-175 cm2 tissue culture flasks (Fisher Scientific, Waltham, 
MA) in expansion media until passage 3 to obtain a homogenous population of precursor cells for 
in vitro studies.  
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3.2.2 Live/dead stain of hASCs on CADDS 
Cytocompatibility assessment was conducted in a 24-well tissue culture plate along with transwell 
tissue culture inserts to suspend the composite hydrogel above the cells in culture medium. Control 
wells were left as a normal tissue culture plastic. Human ASCs were seeded at approximately 1 x 
105 per well in maintenance medium and medium is changed every 2-3 days. On days 5, cells were 
stained with fluorescent Live/Dead viability/cytoxicity kit (Life Technologies, Grand Island, NY). 
A solution of 4 µM calcein and 2 µM ethidium homodimer (EthD-1) was prepared in PBS. The 
solution was added to cells and incubated for 30-45 min at room temperature. Stained cells were 
subsequently rinsed twice with PBS and then observed under fluorescent microscopy to determine 
the viability of the cells. Four treatment conditions were used: Hydrogel adipose ECM, hydrogel 
and single-walled microspheres (SW MS), hydrogel and double-walled microspheres (DW MS), 
and positive control ASCs in maintenance media.  
3.2.3 Alkaline phosphatase (ALP) activity of hASCs with Dex MS 
To access bioactivity of Dex MS, ALP activity was quantified in differentiating cultures of hASC 
containing varied doses of Dex. Concentrations of Dex in differentiation media, from 0 to 800 nM, 
were prepared using Dex MS, according to loading capacity. Human ASC cultures were seeded at 
85,0000 cells/cm2 in 48-well tissue culture polystyrene plate with adipogenic media (StemPro 
Adipogenesis Differentiation Kit, Invitrogen, Inc.) replaced every 2-3 day. Cells were maintained 
and incubated at 37 °C and 5% CO2 for 2 weeks. Alkaline phosphatase activity (ALP) was 
measured using assay kit (BioVision, Milpitas, CA) and plate reader absorbance at 405 nm.  
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3.2.4 Differentiation of hASCs on CADDS 
In vitro differentiation of hASCs with CADDS was conducted to biomaterial interaction with cells, 
specifically adipogenesis. Transwell baskets were used to suspend CADDS (SW), CADDS (DW), 
CADDS (Empty), and Hydrated ECM in culture with hASCs seeded at 85,000 cells/cm2 in 24 well 
plate. Cultures were grown on tissue culture plastic with adipogenic media (StemPro Adipogenesis 
Differentiation Kit, Invitrogen, Inc.) and basal media (DMEM media, 3% FBS, pen/strep, 
fungizone) for positive and negative control, respectively. Cells were maintained and incubated at 
37 °C and 5% CO2 for 2 weeks.  
3.2.5 Oil Red O stain of hASCs on CADDS  
After 2 weeks, hydrogels were removed, and cultures were rinsed with PBS and fixed for an hour 
in 4% formaldehyde. After fixing, cultures were rinsed with sterile water and 60% Isopropanol 
was added to sit for 2 min. Isopropanol solution was moved and replace by Oil Red O working 
solution to sit for 5 minutes. Oil Red O was removed by tap water rinsing and a hematoxylin 
counter stain was used to stain nuclei before the final rinse. Oil red O stock solution was prepared 
by combining 300 mg of Oil Red O powder (Sigma-Aldrich, St. Louis, MO, USA) to 100 ml of 
99% isopropanol. The working solution was developed by using stock dilution of 3:2 (v:v) with 
deionized water. 
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3.2.6 Image J Quantification of Adipogenesis 
Brightfield light microscopy was used to visualize and obtain an objective overview the 
differentiating cultures at 20X magnification. 15 Images (15) were taken at 20X magnification. 
ImageJ was used to compile 15 images of each replicate in experimental group and quantify the 
area of red stained lipids. First, the scale within each image was converted from pixels to 
micrometers. Next, images were converted to grayscale within the RGB stack function. Once in 
grayscale, stained lipids were isolated using the threshold function. Lastly, the threshold area was 
measured as collected for data analysis.  
3.2.7 Lipid Extraction from differentiated hASCs on CADDS 
An additional method was used to quantify the amount of lipids stain by Oil Red O. After 
Brightfield imaging each well, culture plates were placed in 37 C to evaporate any remaining 
water content. Next, 200 l of 100% isopropanol was added to well to wash Oil Red O stain off 
the cells. Lastly, samples were collected and transferred to 96 well plates for measurement by plate 
reader at 510 nm.   
3.2.8 Statistical Analysis 
All quantitative data is presented as a mean ± standard error of the mean. For cell cultures, 
differences between the experimental conditions were calculated for statistical significance by one-
way analysis of variance (ANOVA) using GraphPad Prism 6 (GraphPad Software, Inc.). 
Differences are considered significant if P < 0.05.   
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3.3 RESULTS 
3.3.1 ASC viability on AdECM and CADDS biomaterial 
Cellular biocompatibility was assessed by staining of adipose stem cell cultures in contact with 
AdECM hydrogel and CADDS, compared to a positive control. Overall, quantitative data analysis 
in Figure 17 showed that experimental groups containing hydrogel systems maintained a high 
percentage of cell viability, totaling approximately 80-90% living cells in culture, comparable to 
adipose-derived stems cells alone which had around 92% viable cells after 5 days in culture. 
Representative images of these cultures, Figure 18A-D, consistently reflect a high number of 
viable cells (green fluorescence) compared dead cells (red fluorescence), a similar outcome for all 
groups in the assay. 
 
Figure 17. ASC viability on CADDS biomaterial 
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Figure 18. Live/dead stain of ASCs on (A) AdECM hydrogel, (B) CADDS (SW), (C) CADDS (DW) and (D) 
media (10 um scale bar) 
3.3.2 Bioactivity of Dex MS in ASC culture  
In vitro study results indicate that increased amounts of Dex correlated with ALP intracellular 
activity in groups with higher Dex MS concentration. The trend of ALP intracellular activity in 
ASCs decreased as Dex MS media concentration decreased across the six groups of 800, 400, 200, 
100, 50, and 0 nM Dex, seen in Figure 19.  
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Figure 19. Alkaline phosphatase activity in Dex MS-ASC cultures 
3.3.3 Quantification of adipogenesis 
A 14-day adipogenesis study was conducted to determine the effect of the CADDS on the 
formation of adipocytes in a cell culture. Representative brightfield images in Figure 20 displays 
the differentiation of adipose derived stem cells with clear observational differences in lipid 
accumulation between the positive control and the cells in culture with the CADDS.  
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Figure 20. ImageJ modified images of differentiated hASCs cultured with (A) CADDS (SW), (B) CADDS 
(DW), (C) tissue culture plastic, (D) CADDS (Empty), and (E) Hydrated AdECM 
ImageJ was used to capture, measure, and quantify the amount of lipid accumulation. 
Quantitative results in Figure 21 showed that ASC differentiated samples with CADDS resulted 
in higher amounts of lipid droplets. Additionally, the extracted lipid stains of Oil Red O produced 
similar results with high absorbance measurements from samples with CADDS scaffold in Figure 
22. In both cases of analysis, CADDS DW groups containing the highest degree of lipid content 
and Oil Red O staining.  
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Figure 21. ImageJ quantification of lipid area in differentiated hASC culture 
 
Figure 22. Absorbance readings of Oil Red O extract from differentiated ASCs 
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3.4 DISCUSSION 
By encapsulating the dexamethasone in polymer microspheres, biomaterial scientists are able to 
harness the adipogenic function of Dex for local delivery to the targeted defect site while also 
avoiding the systemic side effects associated with oral administration. Results from the in vitro 
adipogenesis assay demonstrate the ability of dexamethasone released from microspheres to 
increase adipogenesis in adipose derived stem cells compared to cell cultures alone in adipogenic 
media. The dexamethasone and other glucocorticoids are required for the full differentiation of 
adipose precursors and for the maintenance of key genes in glucose and lipid metabolism in 
cultured adipocytes and adipose tissue. As a key component of the composite adipose derived 
delivery system, dexamethasone microspheres can release Dex for several weeks in its single and 
double emulsion form. The SW Dex MS releases a significant portion of the adipogenic drug 
within the first 10 days to initiate adipogenesis in the desired region. This initial burst release 
caused the CADDS SW group to lose the majority of its drug during the first week of the study 
while the CADDS DW group was able to release Dex consistently throughout the study which 
may have led to the higher degree of lipid formation in the ASC differentiation cultures. The single 
layer of PLGA that encapsulates the Dex is hydrolyzed and degrades quickly compared to the DW 
Dex MS formulation which traps the Dex within the inner PLGA core. The PLLA layer 
surrounding the PLGA core degrades much slower due to its methyl side groups causing the 
sustained release of Dex from the DW formulation.  
It was also important to analyze the role of AdECM within the CADDS construct in regard 
to the ASC differentiation studies. The CADDS (Empty MS) and AdECM groups conditions were 
essential to assess the cellular response without Dex MS. Results from the in vitro studies indicate 
 58 
that AdECM is unable to induce a higher degree of lipid formation. Dex MS were required in order 
to influence the adipogenic potential of AdECM in vitro.   
3.5 CONCLUSION 
ASCs are the precursor cells from which adipocytes are formed. In vitro bioactivity studies of 
ASCs with Dex MS demonstrated that increases Dex MS dosage led to a higher degree of cellular 
ALP activity. ASCs were also cultured with CADDS (SW and DW MS) to evaluate viability and 
adipogenic response. ASCs remained highly viable after 5 days in culture with the biomaterial, 
similar to the TCP control, demonstrating a moderate degree a suitability and safety. ASCs 
differentiation on CADDS was also compared to TCP positive control. CADDS containing SW 
and DW microspheres induced ASCs to differentiate to a higher degree and produce a great amount 
of lipids. ASC groups differentiating on CADDS DW were found to have the greatest amount of 
lipid occurrence. Lipid occurrence was analyzed using two different methods which resulted in 
similar outcomes.  
CADDS (SW/DW MS) construct for the purpose of delivering adipogenic bioactive 
molecules represents potential off-the-shelf biomaterial for adipose tissue repair. In this chapter, it 
was demonstrated that CADDS containing SW or DW microspheres positively affects ASC 
differentiation via the release of dexamethasone in cell culture.  
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4.0  IN VIVO RESPONSE AND VOLUME RETENTION OF THE COMPOSITE 
ADIPOSE DERIVED DELIVERY SYSTEM IN SMALL ANIMAL MODEL 
4.1 INTRODUCTION 
A variety of animals has been used in adipose tissue research, each serving a specific purpose. 
Athymic mice are frequently used to assess volume retention of human fat grafts under various 
experimental conditions (microspheres) as well as the growth/differentiation of human ASCs in 
scaffolds within a living system. Athymic mice provide the advantage of physiological conditions 
for a multi-week study without having to match cell-to-animal species. Substantial information 
can be obtained from these studies, but it is distant from clinical application in terms of size, 
function, and immune health.  
The use of an immunocompetent animal such as the Wistar rat is also common. The use of 
allogenic cells, autologous fat, and multi-component scaffolds have been explored and evaluated 
in the Wistar rat model. Materials are normally injected as a bolus subcutaneously with studies 
lasting up to 12 weeks. An animal model with a healthy immune system allows investigators to 
fully consider material degradation and immune responses related to adipose tissue formation. 
Adipose volume retention has been reported in this animal model at 12 weeks (Topcu et al. 2012), 
providing significant data with some clinical relevance. 
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4.2 METHODS 
4.2.1 Pilot In Vivo Volume Retention Study 
Fisher 344 immunocompetent rats were chosen to appropriately assess adipogenic potential of 
CADDS biomaterial in vivo. Rats (n = 16) were divided into 4 groups (n = 4) receiving 
subcutaneous bilateral 1 ml volume injections of hydrated AdECM containing either (1) 300 µg 
dose of SW Dex MS, (2) 300 µg dose of DW Dex MS, (3) Empty MS, or (4) saline only. The 
photograph in Figure 23 shows the implant sites. A 6-week time point was chosen for evaluation 
of biomaterials in regard to explant structure, tissue integration, and volume retention. Photographs 
of the rat were taken each week to observe animal health and outer appearance of implant until the 
end of the study.  
 
Figure 23. Implant sites for volume retention study 
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4.2.2 Surgical Procedure Validation Study 
After high mortality rates occurred in the pilot study, an additional in vivo animal study was 
conducted to validate the safety of surgical procedure for the rats. Rats (6) were divided into 3 
groups (n = 2) receiving either (1) CADDS (SW), (2) Renuva (Musculoskeletal Transplant 
Foundation, Edison, NJ), or (3) sham procedure. The Renuva product was added to compare the 
biological safety of the CADDS material to an industry developed AdECM. A 6-week time point 
was chosen for evaluation of biomaterials in regard to explant structure, tissue integration, and 
volume retention. Photographs of the rat were taken each week to observe animal health and outer 
appearance of implant until the end of the study.   
4.2.3 Implant Surgical Procedure 
All experiments with animals in this study were performed in accordance with the guidelines set 
by the Institutional Animal Care and Use Committee at the University of Pittsburgh in Pittsburgh, 
PA. AdECM and Renvua were reconstituted in sterile saline at a protein concentration of 22.5% 
and implanted subcutaneously on the bilateral dorsal flanks of female Fisher 344 rats using a 
diffuse injection technique. Animals received isoflurane gas during the procedure for 
immobilization and ketoprofen after the procedure for pain management. Over the next 72 hours, 
animals were monitored daily to address any health concerns.    
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4.2.4 Post Implantation Evaluation 
Photos were taken every week for 6 weeks to monitor size of implant over the course of time. 
Additionally, rat weight was recorded to ensure a healthy eating habits resumed after the surgical 
procedure.  
4.2.5 Implant Harvest Procedure and Volume Measurement 
Animals were euthanized by CO2 asphyxiation and cervical dislocation at 6 weeks prior to 
removing the implant. An incision was made above the implantation site to harvest implants from 
underlying subcutaneous tissue. Photos of animals were used to document findings. Half of the 
harvested implants were used for volume measurement via gas pycnometer (AccuPyc II 1340 
Pycnometer, Micrometrics, Norcross, GA). The other half of harvested implants were used for 
histology.  
4.2.6 Histological Analysis 
Immediately after harvesting, implants were placed and submerged in 10% formalin solution as a 
method of fixation. After 8 days, implant tissues were removed and processed for paraffin 
embedding. Once embedded in paraffin blocks, a microtome was used to section samples at 5 m 
for tissue staining. Hematoxylin and Eosin (H&E) staining was conducted to view the overall 
structure of the implant and surrounding tissue. Masson’s Trichrome (M&T) (American 
MasterTech, Lodi, CA) staining was performed according to manufacturer’s protocol. MT staining 
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distinguished the implant from the surrounding animal tissues in the sections. Sections were 
imaged using brightfield microscopy (BZ-X700 Fluorescence microscope, Keyence, Itasca, IL).   
4.2.7 Statistical Analysis 
All quantitative data is presented as a mean ± standard error of the mean. For cell cultures, 
differences between the experimental conditions were calculated for statistical significance by one-
way analysis of variance (ANOVA) using GraphPad Prism 6. (GraphPad Software, Inc.). 
Differences are considered significant if P < 0.05.   
4.3 RESULTS 
4.3.1 Pilot Study Animal Weight and Health 
6 out of the initial 12 animals survived to the end of the pilot study. The remaining 6 animals 
remained healthy and increased their weight according to the range provided by the supplier. In 
Figure 24, animals weighed between 59 to 75 grams at week 0 and increased over time to as high 
as 130 grams. Overall, the animals starting at a lower weight remained smaller than the rest of the 
animals in the study.  
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Figure 24. Volume Retention Study Animal Weight over 6 weeks 
4.3.2 Pilot Study Pycnometer Data 
Half of the harvested implants were used to measure the remaining volume and calculate retention 
(added explant pictures). The hydrated AdECM and CADDS (empty MS) implants had the 
smallest volume with less than 20% of the 1 ml injection remaining as seen in Figure 25. The 
average volume retention rate for CADD (SW) implants was approximately 38%. The harvested 
CADDS (DW) implants were found to have the largest volume remaining after 6 weeks in vivo. 
Retention rates for CADDS (DW) were approximately 50%.   
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Figure 25. Volume Retention of Implants in Pilot Study 
4.3.3 Pilot study explant histology 
Half of the excised implants were fixed, sectioned, and stained with H&E and Masson’s Trichrome 
to assess general structure and morphology of the implant and surrounding tissue. Typically, H&E 
stains nuclei dark blue while cytoplasm and extracellular matrix are stained varying degrees of 
pink. Masson’s trichrome stains the nuclei purple/black, cytoplasm, muscle, erythrocytes and 
keratin bright-red, and blue. Figure 26 and 27 shows the hydrated ECM implant (dark pink/dark 
blue) surrounded by a fibrous capsule (bright pink/bright blue). After 6 weeks, a substantial 
number of mononuclear cells infiltrated the scaffold. Figure 28 shows a noticeably darker CADDS 
SW implant that seemed to degrade at a high degree in the insert microscopy image. The CADDS 
empty implant seemed to have similar results in morphology and degradation as the CADDS SW, 
seen in Figure 30. The CADDS DW implant in Figures 32 and 33 shows a scaffold with darker 
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areas (black/purple) and brighter areas surrounding pockets of adipose-like structure similar to 
adipose tissue found under the skin. 
 
 
Figure 26. Representative image of H&E stained Hydrated AdECM implant section 
 
 
Figure 27. Representative image of Masson's stained Hydrated AdECM implant section 
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Figure 28. Representative image of H&E stained CADDS (SW) implant section 
 
 
Figure 29. Representative image of Masson’s Trichrome stained CADDS (SW) implant section 
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Figure 30. Representative image of H&E stained CADDS (Empty) implant section 
 
 
Figure 31. Representative image of Masson’s trichrome stained CADDS (Empty) implant section 
 69 
 
Figure 32. Representative image of H&E stained CADDS (DW) implant section 
 
 
Figure 33. Representative image of Masson’s trichrome stained CADDS (DW) implant section 
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4.3.4 Validation Study Animal Weight and Health 
All of the animals in the validation study survived to the 6-week surgical procedure validation 
study. All 6 animals remained healthy and increased their weight according to the range provided 
by the supplier. In Figure 34, animals weighed between 98 to 112 grams at week 0 and increased 
with time to as high as 150 grams. By the end of the study, all animals were within a close range 
of 7 grams or less.   
 
 
Figure 34. Surgical Procedure Validation Study Animal Weight over 6 weeks 
4.3.5 Validation Study Pycnometer Data 
Half of the harvested implants were used to measure the remaining volume and calculate retention 
(add explant pictures). The hydrated AdECM and CADDS (empty MS) implants had the smallest 
volume with less than 20% of the 1 ml injection remaining as seen in Figure 35. The average 
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volume retention rate for CADD (SW) implants was approximately 38%. The harvested CADDS 
(DW) implants were found to have the largest volume remaining after 6 weeks in vivo. Retention 
rates for CADDS (DW) were approximately 50%.   
 
Figure 35. Volume Retention of Implants in Procedure Validation Study 
4.3.6 Validation study explant histology 
Half of the excised implants from the validation study were fixed, sectioned, and stained with H&E 
and Masson’s Trichrome. Figure 36 and 37 shows a CADDS (empty) implant infiltrated with 
cellular bodies throughout. Histological sections also seem to show a presence of adipose-like 
structures throughout the capsule and implant interface. The Renuva implant in Figure 38 and 39 
exhibit a very dark shade of pink and blue, respectively. This is most likely cause by a very high 
occurrence of cell infiltration in the implant. Additionally, the implant seems to be detached from 
the capsule interface.   
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Figure 36. Representative image of H&E stained CADDS (Empty) implant section 
 
 
Figure 37. Representative image of Masson’s trichrome stained CADDS (Empty) implant section 
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Figure 38. Representative image of H&E stained Renuva implant section 
 
 
Figure 39. Representative image of Masson’s trichrome stained Renuva implant section 
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4.4 DISCUSSION 
The immunocompetent animal model is essential for the evaluation of implant biomaterials for 
tissue engineering. The response of the functioning immune system to the implanted biomaterials 
provides vital information regarding host response, tissue reconstruction, and 
remodeling/degradation. The majority of the adipose tissue engineering in vivo studies insert the 
respective scaffold subcutaneously similar to the location of an adipose defect area in the clinic.  
The short-term pilot study was designed to observe the initial changes in CADDS scaffold 
structures with and without the release of Dex MS. Unfortunately, only half of the animals survived 
the surgical procedure. However, the remaining animals were able to provide valuable information 
given the multiple inject sites per subject. The volumes of implant scaffolds containing Dex MS 
were higher than scaffolds without Dex. These results suggest that Dex drug delivery may support 
retention in vivo. Similar results were reported in animal studies investigating retention in 
autologous fat grafts (Kelmendi-Doko et al. 2017).  
Histological sections of the pilot study implants demonstrated various degrees of cell 
infiltration, capsule integration, and adipose-tissue like structures. It is worth noting that the 
CADDS DW implant sections contained a noticeable amount of adipose-like structures within the 
construct. Comparatively, the other groups were not about to produce these structures including 
the CADDS SW implants. These results suggest that a slow release of Dex may also support 
positive tissue remodeling in the short term.   
An additional animal study was performed to validate the safety of the surgical procedure 
and compare CADDS (Empty) to an industry manufactured material. All of the animals remained 
viable through the end of the short-term study. The surgical procedure appeared to be safe for the 
animals and resulted in similar retention rates found in Dex-free samples of the initial study. 
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Additionally, CADDS (empty) appeared to promote adipose-like structures formation in 
histological sections without Dex. Longer studies containing a higher population of animals may 
be helpful to clearly defining the role of Dex MS in the CADDS implanted in vivo. However, the 
low retention rates overall from both studies suggest two theories: (1) the immunocompetent rat 
model may be insufficient in assessing CADDS material or (2) the CADDS material promotes an 
insufficient amount of new volume stable adipose tissue. Additional studies were conducted to 
investigate the first theory. It was hypothesized that rat precursor cells (rASCs) from the 
immunocompetent rat will not differentiate on CADDS to the same degree as hASCs in adipogenic 
media.  
4.4.1 Additional Experimentation 
ASCs are an essential population of cells required for new adipose tissue formation. Therefore, 
rASCs should be able to differentiate on scaffold material in an adipogenic environment. In 
Chapter 3, we demonstrated the ability of hASCs to differentiate on CADDS. An in vitro 
differentiation study was designed to identify any differences in adipogenic potential of rASCs 
compared to hASCs on CADDS. 
4.4.2 Methods 
4.4.2.1 Isolation of human ASCs 
Human ASC isolation was conducted as previously reported (Minteer et al. 2015).  
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4.4.2.2 Isolation of rat ASCs 
Subcutaneous adipose depots, particularly the inguinal, dorsolumbar, and axillary, were used to 
isolated adipose tissue of Fischer 344 female rats (Charles River Laboratories, Wilmington, MA). 
Rat adipose tissue was minced in Hank’s Balanced Salt Solution containing 1 mg/ml collagenase 
and 3.5% fatty acid free BSA. Tubes containing minced tissue shaken and submerged in 37 C 
water bath. Once the solution appears homogenous, it is filtered with double layer gauze into a 
sterile tube. Following centrifugation at 1000 rpm for 10 minutes, the supernatant and fatty layer 
is aspirated leaving behind a pellet of cells. Pellet is resuspended in erythrocyte lysis buffer and 
centrifuged again. Next, supernatant of lysis buffer is aspirated leaving behind a pellet to resuspend 
in ASC expansion/growth media and plate in T-75 flask. After 4-6 hours in incubator (37 C and 
5% CO2), cells have attached to culture plate. Finally, cells are washed 3 times with sterile 1X 
PBS and fresh ASC growth media is added to begin feeding. Rat ASCs were expanded on T-175 
cm2 tissue culture flasks (Fisher Scientific, Waltham, MA) in expansion media until passage 3 to 
obtain a homogenous population of precursor cells for in vitro studies. 
4.4.2.3 Flow cytometry of ASCs 
Cultured human or rat ASC cells (passage 3) were analyzed for the expression of various cell 
surface markers using an LSR-II flow cytometer (BD Biosciences). Data were analyzed using 
FlowJo software (Tree Star, OR).  
Antibodies used are listed as following:   Fluorochrome-conjugated mouse anti-human 
CD45 (clone: 2D1, BD Bioscience), mouse anti-rat CD90 (clone: 5E10, BD Bioscience), mouse 
anti-rat CD235a (clone: GA-R2, BD Biosciences), mouse anti-rat CD34 (clone: 581, BD 
Biosciences), mouse anti-rat CD73 (clone: AD2, BD Biosciences), mouse anti-rat CD146 (clone: 
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541-10B2, Miltenyi Biotec), mouse anti-rat CD14(clone: RMO52, Beckman Coulter), mouse anti-
rat CD33 (clone: D3HL60.251, Beckman Coulter), mouse anti-rat CD31 (clone: WM59, 
BioLegend), mouse anti-rat CD105 (clone: N1-3A1/SN6, Fitzgerald). Fluorochrome-conjugated 
mouse anti-rat CD45 (clone: OX-1, BD Biosciences), mouse anti-rat CD90 (clone: OX-7, BD 
Biosciences), mouse anti-rat CD44 (clone: OX-50, BIO-RAD) and hamster anti-rat CD29 (clone: 
Ha2/5, BD Biosciences). 
4.4.2.4 ASC seeding and differentiation on CADDS material 
In vitro studies were conducted on polystyrene 96-well cell culture microplates (Falcon, Fisher 
Scientific, Hampton, NH) for glycerol quantification and black 96 well -plates (ibidi, Fitchburg, 
Wisconsin) for fluorescent staining followed by microscopy. ASCs isolated from human and rat 
adipose were seeded at 30,000 cells per well under the following experimental groups (n=5): tissue 
culture plastic (TCP) with adipogenic media, TCP with basal media, hydrated AdECM with 
adipogenic media, CADDS (SW Dex) with adipogenic media, CADDS (DW Dex) with adipogenic 
media, and CADDS (Emp. MS) with adipogenic media. CADDS and hydrated ECM was prepared 
as previously stated. On day 0 of the 15-day study, 100 l of CADDS or hydrated ECM was 
deposited onto the well plate using 1 ml sterile syringe. Plates were placed in incubator for 3 hours 
to allow scaffolds to stabilize before cell seeding. Expansion media was removed from flasks 
containing ASCs and then rinsed in PBS-EDTA solution to initiate lifting protocol. Cells were 
collected after trypsinization and resuspended in fresh media following centrifugation. Using 
pipette, 30,000 cells were seeded in 50 l of expansion media and allowed to attach to scaffolds 
in the incubator for 1 hour. Lastly, 200 l of expansion media was added each well. On day 1, 
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media was changed to either basal or adipogenic media according to experimental conditions. 
Media changes occurred every 2-3 days until the end of the study.   
4.4.2.5 Nile Red/DAPI stain of differentiated ASCs 
At the last day of the study, media was removed, and cell cultures were gently washed with 1X 
PBS (twice). CADDS/AdECM culture samples were fixed in 4% paraformaldehyde for 30 minutes 
at 4 C. TCP samples were fixed for 10 minutes. After fixation, paraformaldehyde was removed, 
and all samples were rinsed 3 times with 1X PBS. Next, CADDS/AdECM samples were stained 
for 60 minutes with 5 g/ml Nile Red solution (Sigma-Aldrich). TCP samples were stained with 
Nile Red solution for 30 minutes. After rinsing 3 times with 1X PBS, CADDS/AdECM samples 
were stained with DAPI for 15 min. TCP samples were stained with DAPI for 5 min. Once staining 
was complete, all samples were rinsed with 1X PBS 3 times prior to imaging under a fluorescent 
microscope.  
4.4.2.6 Fluorescent imaging of differentiated ASCs on CADDS 
The BZ-X700 (Keyence) Fluorescence microscope was used to obtain fluorescence images of 
differentiated human and rat ASCs. After fixation and staining, cell culture plates were placed into 
the microscope. The Texas Red channel was used to identify lipids stained with Nile Red. The 
DAPI channel was used to identify the stained nuclei. Ten images were taken from each well of 
all experimental conditions at 20X magnification.  
4.4.2.7 Glycerol Assessment of differentiated ASCs on CADDS 
Glycerol release from lipids in differentiated cultures was stimulated by isoproterenol for 1 hour. 
Media was collected after 1 hour in fresh media and saved for measurements. Glycerol content in 
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culture medium across experimental conditions served as an index of lipid accumulation and was 
determined at the absorption of 570 nm by use of a colorimetric assay kit (Glycerol Assay Kit, 
Sigma-Aldrich, St. Louis, MO). Glycerol data was expressed in micromoles of glycerol. 
4.4.3 Results 
4.4.3.1 ASC characterization 
Flow cytometry using antibodies against specific antigens of stem cells was performed. The 
immunotypic profile of hASCs was CD45-, CD146-, CD14-, CD90+, CD73+, CD33+, CD105+, 
CD31+, CD34+, and CD235-, seen in Figure 40. The immunotypic profile of rASCs was CD45-, 
CD29+, CD90+, and CD44+, seen in Figure 41.  
 
Figure 40. Flow Cytometry characterization of hASCs 
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Figure 41. Flow cytometry characterization of rASCs 
4.4.3.2 Microscopy images of hASCs compared to rASCs 
There were observational differences in the cellular behavior between the rASCs and hASCs. In 
Figure 42, a greater degree on hASC differentiation is seen on Hydrated ECM compared to rASC 
differentiation. Differentiation on TCP was comparable between the cell groups containing 
adipogenic media and both ASC groups did not differentiate on TCP in basal media as expected. 
Differences in differentiation is also seen in Figure 43 with microscopic images of hASCs shower 
a higher degree of Nile Red staining on CADDS (empty), CADDS (SW), and CADDS (DW). 
Microscopic images of differentiated rASCs seem to show a trend of cluster cellular structures on 
the CADDS structures as opposed to the spreading seen in differentiated hASC groups. 
Additionally, the hASCs differentiating on CADDS (DW) seemed to result in the highest 
occurrence of Nile Red staining despite the slower release of Dex from the MS.    
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Figure 42. Cultured rASCs and hASCs stained with DAPI/Nile Red 
 
Figure 43. Cultured rASCs and hASCs stained with DAPI/Nile Red 
4.4.3.3 Free Glycerol Quantification 
Differences in glycerol content between differentiated rASCs and hASCs on TCP, hydrated 
AdECM, and CADDS can be seen in Figure 44. Glycerol concentrations were highest for both rat 
and human ASCs on tissue culture plastic compared to other experimental conditions. 
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Comparisons of glycerol content between two species indicate a significantly higher occurrence 
in the hASC cultures on all scaffold material. Additionally, glycerol content was higher for hASCs 
differentiating on CADDS material contain SW and DW MS compared to hydrated ECM and 
CADDS containing empty microspheres.  
 
Figure 44. Glycerol content of differentiated rASCs and hASCs 
4.4.4 Discussion 
ASCs from the human and rat subjects were characterized in regard to the stem phenotype. 
Researchers have confirmed that hASCs with high expressions of CD90, CD 105, CD73, and 
CD44 exhibit the stem phenotype with the ability to differentiate into at least 3 different cell 
lineages (Gir et al. 2012; Minteer et al. 2015; De Francesco et al. 2015). The hASCs used in this 
study also positively expressed these markers. Rat ASCs also expressed progenitor markers with 
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the majority of cells being CD45-, CD29+, CD90+, and CD44+ (Amerion et al. 2018; Ying et al. 
2012). Both species of species possessed the inherent potential to differentiate into multiple cell 
types.  
The differences between differentiated rASC and hASCs on CADDS were evident. 
Observationally, microscope images displayed how rASCs differentiated at a lesser degree and 
clustered on scaffold material. In contrast, hASCs spread across the scaffold and generated more 
lipids indicated by the Nile Red stain. The glycerol content provided a qualitative measurement to 
support the initial findings. Significant differences in glycerol content between rASCs and hASCs 
was found under each condition of scaffold material. The results suggest that rASCs do not possess 
the ability to differentiate on ECM-based scaffolds as well as hASCs. This difference in 
differentiation capacity for rASCs may have contributed to the underwhelming volume retention 
results from the animal studies.  
4.5 CONCLUSION 
Hydrated AdECM and CADDS were implanted in immunocompetent rats to investigate volume 
retention and host tissue response. Overall, the scaffolds were found to be suitable biomaterial 
after the completion of validation study. Although volume retention was unexpectedly low, new 
adipose like-structures were seen in CADDS (DW) implants. Results from in vitro studies showed 
ASCs derived from the immunocompetent rat exhibit limited adipogenic capacity on CADDS. 
Moreover, the immunocompetent rat appears to be an insufficient animal model for assessing the 
volume retention and adipose structure formation from CADDS.  
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5.0  CONCLUSIONS 
A minimally invasive treatment that results in volume-stable, healthy adipose tissue would be an 
ideal therapy for patients with soft tissue defects. A variety of biomaterials, cells, growth factors, 
delivery methods, and culture strategies have been explored resulting in exciting and intriguing 
results that warrant further investigation if their potential. However, it is important to focus on the 
most appropriate avenue to advance clinical applications. Clinical goals for adipose tissue 
replacement include regenerated tissue that both looks and feels similarly to that of native tissue. 
This includes mechanical integrity as well as sustainability and viability of the tissue over time. 
Additionally, adipose tissue that possesses active metabolic function would serve as a significant 
advancement over current adipose tissue engineering strategies.  
Currently, some clinical trials that have been conducted for soft tissue contouring 
applications include a cell-assisted lipotransfer technique developed for cosmetic breast 
augmentation, hyaluronic acid injected into the lips and hands, and face injections containing 
synthetic calcium hydroxylapatite microspheres. Overall, these clinical trials show positive results 
but require bigger population studies to begin establishing a new standard of care. Additionally, 
the current defect requirements for these studies are typically on the order of cubic centimeters. 
Therefore, engineered adipose constructs of significant dimension are necessary. To address this 
particular clinical need, several researchers recommend that significant emphasis on vascularizing 
3D adipose tissue and dynamic pre-cultivation would allow for larger constructs and enhance 
functional adipose tissue formation and maintenance. The ability to deliver appropriate nutrients 
and oxygen to an adipose that is not limited by diffusion, as well as improvements in long-term 
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sustainability of the engineered tissue made through appropriate biomaterial selection, would 
significantly enhance the potential of engineered adipose constructs.  
Naturally derived biomaterials and decellularized proteins are currently dominating the 
research area as the base component of the scaffold. The current project was a reflection this peak 
in interest. We have presented the use of an extensively characterized composite adipose derived 
material containing adipogenic factors as an off the shelf biomaterial. The scaffold was designed 
to address adipose defects especially in cases where autologous fat grafting is not an option. These 
types of scaffolds are still needed in the clinic. 
AdECM and Dex MS are the fundamental components of the CADDS biomaterial. The 
AdECM exhibited favorable characteristics including residual ECM proteins and the removal of 
immunogenic substances such as lipids. Dex MS showed the ability to release Dex quickly and in 
a slower controlled profile over several months. Dex MS also showed bioactivity with hASCs in 
vitro. Additional, in vitro experiments showed that CADDS was adipogenic and increased lipid 
accumulation in hASCs.  
CADDS were implanted in immunocompetent rats as an animal model in the short-term 
evaluation of volume retention, host tissue interaction, and adipose tissue formation. The role of 
Dex MS remains unclear from host tissue interactions. However, Dex MS in CADDS appeared to 
promote moderately higher volume retention. Overall, the low retention rates and lack of adipose 
tissue formation called into question the use of the immunocompetent rat and the adipogenic 
capacity of its ASCs. Additional in vitro studies suggested that rASCs are unable effectively 
differentiate on CADDS which may have played an essential role in the undesirable behavior of 
CADDS in vivo. 
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Next steps include identification of animal models containing ASCs with comparable 
adipogenic potential to hASCs. Once this comparison has been established, the animal model 
should be able to sufficiently assess whether CADDS has the ability to promote adipose formation 
at a high rate of volume retention. Moreover, model should also be used to create a true adipose 
tissue defect that reflects some of the major challenges seen in the clinic. 
It is anticipated that biodegradable biomaterials will continue to dominate the future of 
tissue engineering, specifically adipose tissue. These complex, multi-component scaffolds require 
several fabrication steps to develop each component. With this degree of complexity involved in 
fabricating each scaffold, consistency and standardized batch testing will be of immense 
importance. Although these factors are in the preclinical stage, the addition of personnel with 
controlled drug delivery as well as manufacturing experience in the research lab can give 
investigators a clear advantage for the implementation of their complex biomaterial technology. 
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